WEST Search History

DATE: Monday, December 08, 2003

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ		
L23	colostrinin	23	L23
L22	L21 AND colostrinin	7	L22
L21	((424/85.1 \|424/535)!.CCLS.)	1478	L21
L20	L19 AND colostrinin	2	L20
L19	((530/300 \|530/350)!.CCLS.)	14694	L19
L18	L16 AND colostrinin	3	L18
L17	L16 AND colostronin	0	L17
L16	((514/2 \|514/12 \|514/13 \|514/14 \|514/15 \|514/16 \|514/17 \|514/18)!.CCLS.)	13100	L16
L15	Georgiades-J-A.IN.	5	L15
L14	Georgiades-Jerzy.IN.	1	L14
L13	Georgiades-Jerzy-A.IN.	2	L13
L12	Georgiades.IN.	67	L12
L11	Boldogh.IN.	8	L11
L10	Boldogh-Istvan.IN.	2	L10
L9	Hughes-Thomas-K.IN.	0	L9
L8	Hughes-T-K.IN.	9	L8
L7	Hughes-Thomas.IN.	9	L7
L6	Hughes-Thomas-K.IN.	0	L6
L5	Hughes.IN.	7677	L5
L4	Stanton-G-John.IN.	4	L4
L3	Stanton-G-J.IN.	7	L3
L2	Stanton-G.IN.	4	L2
L1	(Stanton.IN.)	1461	L1

END OF SEARCH HISTORY

NCBI PubMed National Library of Medicine NLM

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

1: Boldogh I, Liebenthal D, Hughes TK, Juelich TL, Georgiades JA, Kruzel ML, Stanton GJ — Related Articles, Links

Modulation of 4HNE-mediated signaling by proline-rich peptides from ovine colostrum.
J Mol Neurosci. 2003 Apr;20(2):125-34.
PMID: 12794306 [PubMed - indexed for MEDLINE]

2: Leszek J, Inglot AD, Janusz M, Byczkiewicz F, Kiejna A, Georgiades J, Lisowski J. — Related Articles, Links

Colostrinin proline-rich polypeptide complex from ovine colostrum--a long-term study of its efficacy in Alzheimer's disease.
Med Sci Monit. 2002 Oct;8(10):PI93-6.
PMID: 12388930 [PubMed - indexed for MEDLINE]

3: Kruzel ML, Janusz M, Lisowski J, Fischleigh RV, Georgiades JA. — Related Articles, Links

Towards an understanding of biological role of colostrinin peptides.
J Mol Neurosci. 2001 Dec;17(3):379-89.
PMID: 11859934 [PubMed - indexed for MEDLINE]

4: Popik P. — Related Articles, Links

Colostrinin and colostrinin-derived nonapeptide (colostral-val nonapeptide, CVNP) facilitate learning and memory in rats.
Pol J Pharmacol. 2001 Mar-Apr;53(2):166-8. No abstract available.
PMID: 11787957 [PubMed - indexed for MEDLINE]

5: Popik P, Galoch Z, Janusz M, Lisowski J, Vetulani J. — Related Articles, Links

Cognitive effects of Colostral-Val nonapeptide in aged rats.
Behav Brain Res. 2001 Jan 29;118(2):201-8.
PMID: 11164518 [PubMed - indexed for MEDLINE]

6: Leszek J, Inglot AD, Janusz M, Lisowski J, Krukowska K, Georgiades JA. — Related Articles, Links

Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study.
Arch Immunol Ther Exp (Warsz). 1999;47(6):377-85.
PMID: 10608295 [PubMed - indexed for MEDLINE]

7: Popik P, Bobula B, Janusz M, Lisowski J, Vetulani J. — Related Articles, Links

Colostrinin, a polypeptide isolated from early milk, facilitates learning and memory in rats.
Pharmacol Biochem Behav. 1999 Sep;64(1):183-9.
PMID: 10495015 [PubMed - indexed for MEDLINE]

8: Sokal I, Janusz M, Miecznikowska H, Kupryszewski G, Lisowski J. — Related Articles, Links

Effect of colostrinin, an immunomodulatory proline-rich polypeptide from ovine colostrum, on sialidase and beta-galactosidase activities in murine

thymocytes.
Arch Immunol Ther Exp (Warsz). 1998;46(3):193-8.
PMID: 9704152 [PubMed - indexed for MEDLINE]

9: Inglot AD, Gelder F, Georgiades JA. Related Articles, Links

Tumor-associated antigens are cytokine inducers and hyporeactivity factors to the immune system.
Biotherapy. 1998;11(1):27-37.
PMID: 9617463 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Items 1-9 of 9 One page.

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Dec 1 2003 07:03:59

h cb h g e e e fcg b e

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure PMC Journals Book

Search PubMed for colostrum AND cytokine Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

Display Summary Show: 500 Sort Send to Text

Items 1-152 of 152 One page.

1: Juul SE. Links

Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates.
J Pediatr. 2003 Sep;143(3):321-6.
PMID: 14517513 [PubMed - indexed for MEDLINE]

2: Yamanaka H, Hagiwara K, Kirisawa R, Iwai H. Links

Transient detection of proinflammatory cytokines in sera of colostrum-fed newborn calves.
J Vet Med Sci. 2003 Jul;65(7):813-6.
PMID: 12939511 [PubMed - indexed for MEDLINE]

3: Yamanaka H, Hagiwara K, Kirisawa R, Iwai H. Links

Proinflammatory cytokines in bovine colostrum potentiate the mitogenic response of peripheral blood mononuclear cells from newborn calves through IL-2 and CD25 expression.
Microbiol Immunol. 2003;47(6):461-8.
PMID: 12906107 [PubMed - indexed for MEDLINE]

4: Calhoun DA, Maheshwari A, Christensen RD. Links

Recombinant granulocyte colony-stimulating factor administered enterally to neonates is not absorbed.
Pediatrics. 2003 Aug;112(2):421-3.
PMID: 12897302 [PubMed - indexed for MEDLINE]

5: Takahata Y, Takada H, Nomura A, Nakayama H, Ohshima K, Hara T. Links

Detection of interferon-gamma-inducible chemokines in human milk.
Acta Paediatr. 2003 Jun;92(6):659-65.
PMID: 12856973 [PubMed - indexed for MEDLINE]

6: Buckley JD, Brinkworth GD, Abbott MJ. Links

Effect of bovine colostrum on anaerobic exercise performance and plasma insulin-like growth factor I.
J Sports Sci. 2003 Jul;21(7):577-88.
PMID: 12848392 [PubMed - indexed for MEDLINE]

7: Ontsouka CE, Bruckmaier RM, Blum JW. Links

Fractionized milk composition during removal of colostrum and mature milk.
J Dairy Sci. 2003 Jun;86(6):2005-11.
PMID: 12836936 [PubMed - indexed for MEDLINE]

8: Juul SE, Christensen RD. Links

Absorption of enteral recombinant human erythropoietin by neonates.
Ann Pharmacother. 2003 Jun;37(6):782-6.
PMID: 12773061 [PubMed - indexed for MEDLINE]

9: Bottcher MF, Jenmalm MC, Bjorksten B. Links

Cytokine, chemokine and secretory IgA levels in human milk in relation to atopic disease and IgA production in infants.
Pediatr Allergy Immunol. 2003 Feb;14(1):35-41.
PMID: 12603709 [PubMed - indexed for MEDLINE]

10: Bottcher MF, Fredriksson J, Hellquist A, Jenmalm MC. Links

Effects of breast milk from allergic and non-allergic mothers on mitogen- and allergen-induced cytokine production.
Pediatr Allergy Immunol. 2003 Feb;14(1):27-34.
PMID: 12603708 [PubMed - indexed for MEDLINE]

11: Bolke E, Orth K, Jehle PM, Schwarz A, Steinbach G, Schleich S, Ulmer C, Storck M, Hannekum A. Links

Enteral application of an immunoglobulin-enriched colostrum milk preparation for reducing endotoxin translocation and acute phase response in patients undergoing coronary bypass surgery--a randomized placebo-controlled pilot trial.
Wien Klin Wochenschr. 2002 Nov 30;114(21-22):923-8.
PMID: 12528325 [PubMed - indexed for MEDLINE]

12: Calhoun DA. Links

Enteral administration of hematopoietic growth factors in the neonatal intensive care unit.
Acta Paediatr Suppl. 2002;91(438):43-53. Review.
PMID: 12477264 [PubMed - indexed for MEDLINE]

13: Nishimura S, Maeno N, Matsuo K, Nakajima T, Kitajima I, Saito H, Maruyama I. Links

Human lactiferous mammary gland cells produce vascular endothelial growth factor (VEGF) and express the VEGF receptors, Flt-1 AND KDR/Flk-1.
Cytokine. 2002 May 21;18(4):191-8.
PMID: 12126641 [PubMed - indexed for MEDLINE]

14: Hashira S, Okitsu-Negishi S, Yoshino K. Links

Interleukin 8 in the human colostrum.
Biol Neonate. 2002;82(1):34-8.
PMID: 12119539 [PubMed - indexed for MEDLINE]

15: Pedersen AM, Andersen TL, Reibel J, Holmstrup P, Nauntofte B. Links

Oral findings in patients with primary Sjogren's syndrome and oral lichen planus--a preliminary study on the effects of bovine colostrum-containing oral hygiene products.
Clin Oral Investig. 2002 Mar;6(1):11-20.
PMID: 11996158 [PubMed - indexed for MEDLINE]

16: Flores M, Filteau S. Links

Effect of lactation counselling on subclinical mastitis among Bangladeshi women.
Ann Trop Paediatr. 2002 Mar;22(1):85-8.
PMID: 11926056 [PubMed - indexed for MEDLINE]

17: Kruzel ML, Janusz M, Lisowski J, Fischleigh RV, Georgiades JA. Links

Towards an understanding of biological role of colostrinin peptides.
J Mol Neurosci. 2001 Dec;17(3):379-89.
PMID: 11859934 [PubMed - indexed for MEDLINE]

Bolke E, Jehle PM, Hausmann F, Daubler A, Wiedeck H, Steinbach G, Storck M, Links

18: Orth K.

Preoperative oral application of immunoglobulin-enriched colostrum milk and mediator response during abdominal surgery.
Shock. 2002 Jan;17(1):9-12.
PMID: 11795674 [PubMed - indexed for MEDLINE]

19: Kelleher SL, Lonnerdal B. Links

Immunological activities associated with milk.
Adv Nutr Res. 2001;10:39-65. Review.
PMID: 11795053 [PubMed - indexed for MEDLINE]

20: Filteau SM. Links

Milk components with immunomodulatory potential.
Adv Nutr Res. 2001;10:327-50. Review. No abstract available.
PMID: 11795049 [PubMed - indexed for MEDLINE]

21: Barrington GM, Parish SM. Links

Bovine neonatal immunology.
Vet Clin North Am Food Anim Pract. 2001 Nov;17(3):463-76. Review.
PMID: 11692503 [PubMed - indexed for MEDLINE]

22: Zabłocka A, Janusz M, Rybka K, Wirkus-Romanowska I, Kupryszewski G, Lisowski J. Links

Cytokine-inducing activity of a proline-rich polypeptide complex (PRP) from ovine colostrum and its active nonapeptide fragment analogs.
Eur Cytokine Netw. 2001 Jul-Sep;12(3):462-7.
PMID: 11566627 [PubMed - indexed for MEDLINE]

23: Yamanaka H, Katagiri Y, Domi M, Hagiwara K, Kirisawa R, Iwai H. Links

Effect of interleukin-1 receptor antagonist on concanavalin A response of peripheral blood mononuclear cells from newborn calves.
J Vet Med Sci. 2001 Aug;63(8):933-5.
PMID: 11558554 [PubMed - indexed for MEDLINE]

24: Lemaire M, Schynts F, Meyer G, Georgin JP, Baranowski E, Gabriel A, Ros C, Belak S, Thiry E. Links

Latency and reactivation of a glycoprotein E negative bovine herpesvirus type 1 vaccine: influence of virus load and effect of specific maternal antibodies.
Vaccine. 2001 Sep 14;19(32):4795-804.
PMID: 11535332 [PubMed - indexed for MEDLINE]

25: Takahata Y, Takada H, Nomura A, Ohshima K, Nakayama H, Tsuda T, Nakano H, Hara T. Links

Interleukin-18 in human milk.
Pediatr Res. 2001 Aug;50(2):268-72.
PMID: 11477214 [PubMed - indexed for MEDLINE]

26: Riffault S, Carrat C, van Reeth K, Pensaert M, Charley B. Links

Interferon-alpha-producing cells are localized in gut-associated lymphoid tissues in transmissible gastroenteritis virus (TGEV) infected piglets.
Vet Res. 2001 Jan-Feb;32(1):71-9.
PMID: 11254179 [PubMed - indexed for MEDLINE]

27: Bastian SE, Dunbar AJ, Priebe IK, Owens PC, Goddard C. Links

Measurement of betacellulin levels in bovine serum, colostrum and milk.
J Endocrinol. 2001 Jan;168(1):203-12.
PMID: 11139784 [PubMed - indexed for MEDLINE]

28: Mutwiri G, Bateman C, Baca-Estrada ME, Snider M, Griebel P. Links

Induction of immune responses in newborn lambs following enteric immunization with a human adenovirus vaccine vector.
Vaccine. 2000 Dec 8;19(9-10):1284-93.
PMID: 11137268 [PubMed - indexed for MEDLINE]

29: Kalliomaki M, Isolauri E. Links

Breastfeeding and atopic sensitisation.
Adv Exp Med Biol. 2000;478:389-90. No abstract available.
PMID: 11065096 [PubMed - indexed for MEDLINE]

30: Saarinen KM, Juntunen-Backman K, Jarvenpaa AL, Klemetti P, Kuitunen P, Lope L, Renlund M, Siivola M, Vaarala O, Savilahti E. Links

Breast-feeding and the development of cows' milk protein allergy.
Adv Exp Med Biol. 2000;478:121-30.
PMID: 11065065 [PubMed - indexed for MEDLINE]

31: Vuorela P, Andersson S, Carpen O, Ylikorkala O, Halmesmaki E. Links

Unbound vascular endothelial growth factor and its receptors in breast, human milk, and newborn intestine.
Am J Clin Nutr. 2000 Nov;72(5):1196-201.
PMID: 11063449 [PubMed - indexed for MEDLINE]

32: Hoshimoto K, Ohkura T. Links

Vascular endothelial growth factor in human milk.
Br J Biomed Sci. 2000;57(3):215-7. No abstract available.
PMID: 11050773 [PubMed - indexed for MEDLINE]

33: Hagiwara K, Kataoka S, Yamanaka H, Kirisawa R, Iwai H. Links

Detection of cytokines in bovine colostrum.
Vet Immunol Immunopathol. 2000 Oct 31;76(3-4):183-90.
PMID: 11044552 [PubMed - indexed for MEDLINE]

34: Pacha J. Links

Development of intestinal transport function in mammals.
Physiol Rev. 2000 Oct;80(4):1633-67. Review.
PMID: 11015621 [PubMed - indexed for MEDLINE]

35: Nobiron I, Thompson I, Brownlie J, Collins ME. Links

Co-administration of IL-2 enhances antigen-specific immune responses following vaccination with DNA encoding the glycoprotein E2 of bovine viral diarrhoea virus.
Vet Microbiol. 2000 Sep 25;76(2):129-42.
PMID: 10946143 [PubMed - indexed for MEDLINE]

36: Van Reeth K, Nauwynck H, Pensaert M. Links

A potential role for tumour necrosis factor-alpha in synergy between porcine respiratory coronavirus and bacterial lipopolysaccharide in the induction of respiratory disease in pigs.
J Med Microbiol. 2000 Jul;49(7):613-20.
PMID: 10882086 [PubMed - indexed for MEDLINE]

37: Playford RJ, Macdonald CE, Johnson WS. Links

Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders.
Am J Clin Nutr. 2000 Jul;72(1):5-14. Review.
PMID: 10871554 [PubMed - indexed for MEDLINE]

38: Bottcher MF, Jenmalm MC, Bjorksten B, Garofalo RP. Links

Chemoattractant factors in breast milk from allergic and nonallergic mothers.
Pediatr Res. 2000 May;47(5):592-7.
PMID: 10813582 [PubMed - indexed for MEDLINE]

39: Lemaire M, Weynants V, Godfroid J, Schynts F, Meyer G, Letesson JJ, Thiry E. Links

Effects of bovine herpesvirus type 1 infection in calves with maternal antibodies on immune response and virus latency.
J Clin Microbiol. 2000 May;38(5):1885-94.
PMID: 10790117 [PubMed - indexed for MEDLINE]

40: Fournout S, Dozois CM, Odin M, Desautels C, Peres S, Herault F, Daigle F, Segafredo C, Laffitte J, Oswald E, Fairbrother JM, Oswald IP. Links

Lack of a role of cytotoxic necrotizing factor 1 toxin from Escherichia coli in bacterial pathogenicity and host cytokine response in infected germfree piglets.
Infect Immun. 2000 Feb;68(2):839-47.
PMID: 10639454 [PubMed - indexed for MEDLINE]

41: Bottcher MF, Jenmalm MC, Garofalo RP, Bjorksten B. Links

Cytokines in breast milk from allergic and nonallergic mothers.
Pediatr Res. 2000 Jan;47(1):157-62.
PMID: 10625097 [PubMed - indexed for MEDLINE]

42: Leszek J, Inglot AD, Janusz M, Lisowski J, Krukowska K, Georgiades JA. Links

Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study.
Arch Immunol Ther Exp (Warsz). 1999;47(6):377-85.
PMID: 10608295 [PubMed - indexed for MEDLINE]

43: Kalliomaki M, Ouwehand A, Arvilommi H, Kero P, Isolauri E. Links

Transforming growth factor-beta in breast milk: a potential regulator of atopic disease at an early age.
J Allergy Clin Immunol. 1999 Dec;104(6):1251-7.
PMID: 10589009 [PubMed - indexed for MEDLINE]

44: Saarinen KM, Vaarala O, Klemetti P, Savilahti E. Links

Transforming growth factor-beta1 in mothers' colostrum and immune responses to cows' milk proteins in infants with cows' milk allergy.
J Allergy Clin Immunol. 1999 Nov;104(5):1093-8.
PMID: 10550758 [PubMed - indexed for MEDLINE]

45: Domaraczenko B, Janusz M, Orzechowska B, Jarosz W, Blach-Olszewska Z. Links

Effect of proline rich polypeptide from ovine colostrum on virus replication in human placenta and amniotic membrane at term; possible role of endogenous tumour necrosis factor alpha.
Placenta. 1999 Nov;20(8):695-701.
PMID: 10527824 [PubMed - indexed for MEDLINE]

46: Habata Y, Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Hinuma S, Kitada C, Nishizawa N, Murosaki S, Kurokawa T, Onda H, Tatemoto K, Fujino M. Links

Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum.
Biochim Biophys Acta. 1999 Oct 13;1452(1):25-35.
PMID: 10525157 [PubMed - indexed for MEDLINE]

47: Van Reeth K, Labarque G, Nauwynck H, Pensaert M. Links

Differential production of proinflammatory cytokines in the pig lung during different respiratory virus infections: correlations with pathogenicity.
Res Vet Sci. 1999 Aug;67(1):47-52.
PMID: 10425240 [PubMed - indexed for MEDLINE]

48: Bryan DL, Hawkes JS, Gibson RA. Links

Interleukin-12 in human milk.
Pediatr Res. 1999 Jun;45(6):858-9.
PMID: 10367778 [PubMed - indexed for MEDLINE]

49: Playford RJ, Floyd DN, Macdonald CE, Calnan DP, Adenekan RO, Johnson W, Goodlad RA, Marchbank T. Links

Bovine colostrum is a health food supplement which prevents NSAID induced gut damage.
Gut. 1999 May;44(5):653-8.
PMID: 10205201 [PubMed - indexed for MEDLINE]

50: Lemaire M, Schynts F, Meyer G, Thiry E. Links

Antibody response to glycoprotein E after bovine herpesvirus type 1 infection in passively immunised, glycoprotein E-negative calves.
Vet Rec. 1999 Feb 13;144(7):172-6.
PMID: 10097325 [PubMed - indexed for MEDLINE]

51: Rajaraman V, Nonnecke BJ, Franklin ST, Hammell DC, Horst RL. Links

Effect of vitamins A and E on nitric oxide production by blood mononuclear leukocytes from neonatal calves fed milk replacer.
J Dairy Sci. 1998 Dec;81(12):3278-85.
PMID: 9891273 [PubMed - indexed for MEDLINE]

52: Xu R, Doan QC, Regester GO. Links

Detection and characterisation of transforming growth factor-beta in porcine colostrum.
Biol Neonate. 1999;75(1):59-64.
PMID: 9831685 [PubMed - indexed for MEDLINE]

53: Ginjala V, Pakkanen R. Links

Determination of transforming growth factor-beta 1 (TGF-beta 1) and insulin-like growth factor (IGF-1) in bovine colostrum samples.
J Immunoassay. 1998 May-Aug;19(2-3):195-207.
PMID: 9682131 [PubMed - indexed for MEDLINE]

54: Michie CA, Tantscher E, Schall T, Rot A. Links

Physiological secretion of chemokines in human breast milk.
Eur Cytokine Netw. 1998 Jun;9(2):123-9.
PMID: 9681387 [PubMed - indexed for MEDLINE]

55: Buescher ES, McWilliams-Koeppen P. Links

Soluble tumor necrosis factor-alpha (TNF-alpha) receptors in human colostrum and milk bind to TNF-alpha and neutralize TNF-alpha bioactivity.
Pediatr Res. 1998 Jul;44(1):37-42.
PMID: 9667368 [PubMed - indexed for MEDLINE]

56: Van Reeth K, Nauwynck H, Pensaert M. Links

Bronchoalveolar interferon-alpha, tumor necrosis factor-alpha, interleukin-

1, and inflammation during acute influenza in pigs: a possible model for humans?
J Infect Dis. 1998 Apr;177(4):1076-9.
PMID: 9534986 [PubMed - indexed for MEDLINE]

57: Pakkanen R. Links

Determination of transforming growth factor-beta 2 (TGF-beta 2) in bovine colostrum samples.
J Immunoassay. 1998 Feb;19(1):23-37.
PMID: 9530609 [PubMed - indexed for MEDLINE]

58: Flidel-Rimon O, Roth P. Links

Effects of milk-borne colony stimulating factor-1 on circulating growth factor levels in the newborn infant.
J Pediatr. 1997 Nov;131(5):748-50.
PMID: 9403658 [PubMed - indexed for MEDLINE]

59: Rajaraman V, Nonnecke BJ, Horst RL. Links

Effects of replacement of native fat in colostrum and milk with coconut oil on fat-soluble vitamins in serum and immune function in calves.
J Dairy Sci. 1997 Oct;80(10):2380-90.
PMID: 9361210 [PubMed - indexed for MEDLINE]

60: Trahair JF, Sangild PT. Links

Systemic and luminal influences on the perinatal development of the gut.
Equine Vet J Suppl. 1997 Jun;(24):40-50. Review.
PMID: 9355801 [PubMed - indexed for MEDLINE]

61: Pabst HF. Links

Immunomodulation by breast-feeding.
Pediatr Infect Dis J. 1997 Oct;16(10):991-5. Review. No abstract available.
PMID: 9380478 [PubMed - indexed for MEDLINE]

62: Quan CP, Berneman A, Pires R, Avrameas S, Bouvet JP. Links

Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans.
Infect Immun. 1997 Oct;65(10):3997-4004.
PMID: 9316998 [PubMed - indexed for MEDLINE]

63: Yoshida A, Suzuki M, Ikenaga H, Takeuchi M. Links

Discovery of the shortest sequence motif for high level mucin-type O-glycosylation.
J Biol Chem. 1997 Jul 4;272(27):16884-8.
PMID: 9201996 [PubMed - indexed for MEDLINE]

64: Goto M, Maruyama M, Kitadate K, Kirisawa R, Obata Y, Koiwa M, Iwai H. Links

Detection of interleukin-1 beta in sera and colostrum of dairy cattle and in sera of neonates.
J Vet Med Sci. 1997 Jun;59(6):437-41.
PMID: 9234217 [PubMed - indexed for MEDLINE]

65: Numazaki K. Links

Human cytomegalovirus infection of breast milk.
FEMS Immunol Med Microbiol. 1997 Jun;18(2):91-8. Review.
PMID: 9223612 [PubMed - indexed for MEDLINE]

66: Wong CW, Liu AH, Regester GO, Francis GL, Watson DL. Links

h cb h g e e e fcg e ch b e

Influence of whey and purified whey proteins on neutrophil functions in sheep.
J Dairy Res. 1997 May;64(2):281-8.
PMID: 9161920 [PubMed - indexed for MEDLINE]

67: Piasecki E, Inglot AD, Winiarska M, Krukowska K, Janusz M, Lisowski J. Links

Coincidence between spontaneous release of interferon and tumor necrosis factor by colostral leukocytes and the production of a colostrinine by human mammary gland after normal delivery.
Arch Immunol Ther Exp (Warsz). 1997;45(1):109-17.
PMID: 9090449 [PubMed - indexed for MEDLINE]

68: Blach-Olszewska Z, Janusz M. Links

Stimulatory effect of ovine colostrinine (a proline-rich polypeptide) on interferons and tumor necrosis factor production by murine resident peritoneal cells.
Arch Immunol Ther Exp (Warsz). 1997;45(1):43-7.
PMID: 9090439 [PubMed - indexed for MEDLINE]

69: Bertotto A, Vagliasindi C, Gerli R, Spinozzi F, Castellucci G, Fabietti G, Crupi S, Radicioni M, Cozzali R, Ferraro L, Niccoli A, De Rosa O, Lupi C, Brunelli R, Merluzzi A, Guadalupi D, Parente C, Pertici L, Serra M, Vaccaro R. Links

Soluble CD30 antigen in human colostrum.
Biol Neonate. 1997;71(2):69-74.
PMID: 9057989 [PubMed - indexed for MEDLINE]

70: Buescher ES, Malinowska I. Links

Soluble receptors and cytokine antagonists in human milk.
Pediatr Res. 1996 Dec;40(6):839-44.
PMID: 8947960 [PubMed - indexed for MEDLINE]

71: Srivastava MD, Srivastava A, Brouhard B, Saneto R, Groh-Wargo S, Kubit J. Links

Cytokines in human milk.
Res Commun Mol Pathol Pharmacol. 1996 Sep;93(3):263-87.
PMID: 8896040 [PubMed - indexed for MEDLINE]

72: Ackermann MR, Register KB, Stabel JR, Gwaltney SM, Howe TS, Rimler RB. Links

Effect of Pasteurella multocida toxin on physeal growth in young pigs.
Am J Vet Res. 1996 Jun;57(6):848-52.
PMID: 8725812 [PubMed - indexed for MEDLINE]

73: Wong CW, Regester GO, Francis GL, Watson DL. Links

Immunomodulatory activities of whey fractions in efferent prefemoral lymph of sheep.
J Dairy Res. 1996 May;63(2):257-67.
PMID: 8861347 [PubMed - indexed for MEDLINE]

74: Talhouk RS, Neiswander RL, Schanbacher FL. Links

Developmental regulation and partial characterization of growth factors in the bovine mammary gland.
J Reprod Fertil. 1996 Mar;106(2):221-30.
PMID: 8699405 [PubMed - indexed for MEDLINE]

75: Ellis JA, Hassard LE, Cortese VS, Morley PS. Links

Effects of perinatal vaccination on humoral and cellular immune responses in cows and young calves.
J Am Vet Med Assoc. 1996 Feb 1;208(3):393-400.
PMID: 8575972 [PubMed - indexed for MEDLINE]

76: Inglot AD, Janusz M, Lisowski J. Links

Colostrinine: a proline-rich polypeptide from ovine colostrum is a modest cytokine inducer in human leukocytes.
Arch Immunol Ther Exp (Warsz). 1996;44(4):215-24.
PMID: 9017161 [PubMed - indexed for MEDLINE]

77: Sambasivarao D, Hooton J, Dost A, Paetkau V. Links

A novel immunosuppressive factor in bovine colostrum blocks activation of the interleukin 2 gene enhancer at the NFAT site.
Biochem Cell Biol. 1996;74(4):585-93.
PMID: 8960365 [PubMed - indexed for MEDLINE]

78: Bessler H, Straussberg R, Hart J, Notti I, Sirota L. Links

Human colostrum stimulates cytokine production.
Biol Neonate. 1996;69(6):376-82.
PMID: 8862463 [PubMed - indexed for MEDLINE]

79: Le Jan C. Links

Cellular components of mammary secretions and neonatal immunity: a review.
Vet Res. 1996;27(4-5):403-17. Review.
PMID: 8822611 [PubMed - indexed for MEDLINE]

80: Kishikawa Y, Watanabe T, Watanabe T, Kubo S. Links

Purification and characterization of cell growth factor in bovine colostrum.
J Vet Med Sci. 1996 Jan;58(1):47-53.
PMID: 8645756 [PubMed - indexed for MEDLINE]

81: Sirota L, Straussberg R, Notti I, Bessler H. Links

Effect of human colostrum on interleukin-2 production and natural killer cell activity.
Arch Dis Child Fetal Neonatal Ed. 1995 Sep;73(2):F99-102.
PMID: 7583615 [PubMed - indexed for MEDLINE]

82: Nikolova EB, Russell MW. Links

Dual function of human IgA antibodies: inhibition of phagocytosis in circulating neutrophils and enhancement of responses in IL-8-stimulated cells.
J Leukoc Biol. 1995 Jun;57(6):875-82.
PMID: 7790770 [PubMed - indexed for MEDLINE]

83: Kandefer-Szerszen M, Szuster-Ciesielska A, Zdzisinska B, Kaminska T, Kondracki M. Links

In vitro and in vivo interferon production by bovine colostral leukocytes.
Dtsch Tierarztl Wochenschr. 1995 May;102(5):190-2.
PMID: 8593770 [PubMed - indexed for MEDLINE]

84: Mandalapu P, Pabst HF, Paetkau V. Links

A novel immunosuppressive factor in human colostrum.
Cell Immunol. 1995 May;162(2):178-84.
PMID: 7743544 [PubMed - indexed for MEDLINE]

85: Mori K. Links

[Studies on expression and function of Eta-1(early T lymphocyte activation-1) in autoimmune prone MRL/Mp-lpr/lpr mice]
Hokkaido Igaku Zasshi. 1994 Jul;69(4):708-17. Japanese.
PMID: 7525433 [PubMed - indexed for MEDLINE]

86: Rewinski MJ, Yang TJ. Links

Lactation stage-dependent changes in levels of tumor necrosis factor/cachectin in milk.
Am J Reprod Immunol. 1994 May;31(4):170-6.
PMID: 8060499 [PubMed - indexed for MEDLINE]

87: Schams D. Links

Growth factors in milk.
Endocr Regul. 1994 Mar;28(1):3-8. Review.
PMID: 7949010 [PubMed - indexed for MEDLINE]

88: Baumrucker CR, Blum JW. Links

Effects of dietary recombinant human insulin-like growth factor-I on concentrations of hormones and growth factors in the blood of newborn calves.
J Endocrinol. 1994 Jan;140(1):15-21.
PMID: 8138748 [PubMed - indexed for MEDLINE]

89: Kandefer-Szerszen M, Kondracki M, Szuster-Ciesielska A, Rzeski W, Zdzisinska B, Cakala S. Links

Influence of the perinatal period on bovine interferon production.
Arch Immunol Ther Exp (Warsz). 1994;42(4):307-11.
PMID: 7487372 [PubMed - indexed for MEDLINE]

90: O'Connell BC, Tabak LA. Links

A comparison of serine and threonine O-glycosylation by UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase.
J Dent Res. 1993 Dec;72(12):1554-8.
PMID: 8254121 [PubMed - indexed for MEDLINE]

91: Grosvenor CE, Picciano MF, Baumrucker CR. Links

Hormones and growth factors in milk.
Endocr Rev. 1993 Dec;14(6):710-28. Review.
PMID: 8119234 [PubMed - indexed for MEDLINE]

92: Saito S, Yoshida M, Ichijo M, Ishizaka S, Tsujii T. Links

Transforming growth factor-beta (TGF-beta) in human milk.
Clin Exp Immunol. 1993 Oct;94(1):220-4.
PMID: 8403511 [PubMed - indexed for MEDLINE]

93: de Gorgolas Hernandez-Mora M, Verdejo Morcillo C, Fernandez Guerrero ML. Links

[Therapeutic approaches to cryptosporidiosis. A review of the literature]
Rev Clin Esp. 1993 Oct;193(6):322-8. Review. Spanish.
PMID: 8259458 [PubMed - indexed for MEDLINE]

94: Robinson JA, Allen GK, Green EM, Garner HE, Loch WE, Walsh DM. Links

Serum interleukin-6 concentrations in endotoxin-infused neonatal foals.
Am J Vet Res. 1993 Sep;54(9):1411-4.
PMID: 8239126 [PubMed - indexed for MEDLINE]

95: Allen GK, Green EM, Robinson JA, Garner HE, Loch WE, Walsh DM. Links

Serum tumor necrosis factor alpha concentrations and clinical abnormalities in colostrum-fed and colostrum-deprived neonatal foals given endotoxin.
Am J Vet Res. 1993 Sep;54(9):1404-10.
PMID: 8239125 [PubMed - indexed for MEDLINE]

96: Mellor DJ. Links

Some aspects of perinatal maturation and adaptation.
Equine Vet J Suppl. 1993 Apr;(14):17-22. Review.
PMID: 9079131 [PubMed - indexed for MEDLINE]

97: Bocci V, von Bremen K, Corradeschi F, Franchi F, Luzzi E, Paulesu L. Links

Presence of interferon-gamma and interleukin-6 in colostrum of normal women.
Lymphokine Cytokine Res. 1993 Feb;12(1):21-4.
PMID: 8457628 [PubMed - indexed for MEDLINE]

98: Tokuyama Y, Tokuyama H. Links

Purification and identification of TGF-beta 2-related growth factor from bovine colostrum.
J Dairy Res. 1993 Feb;60(1):99-109.
PMID: 8436667 [PubMed - indexed for MEDLINE]

99: Martinez-Cairo Cueto S, Alasio-Chavez C, Davila Velazquez JR. Links

[In vitro transfer of immunity against PPD with dialyzable extract of leukocytes from human colostrum]
Rev Alerg. 1992 Nov-Dec;39(6):126-32. Spanish.
PMID: 1492196 [PubMed - indexed for MEDLINE]

100: Shinmoto H, Dosako S, Tanaka S. Links

Transformation of human colostrum lymphocytes with Epstein-Barr virus.
Tokai J Exp Clin Med. 1992 Oct;17(3-4):129-32.
PMID: 1338659 [PubMed - indexed for MEDLINE]

101: Watson DL, Francis GL, Ballard FJ. Links

Factors in ruminant colostrum that influence cell growth and murine IgE antibody responses.
J Dairy Res. 1992 Aug;59(3):369-80.
PMID: 1401358 [PubMed - indexed for MEDLINE]

102: Lehn M, Kandil O, Arena C, Rein MS, Remold HG. Links

Interleukin-4 fails to inhibit interferon-gamma-induced activation of human colostral macrophages.
Cell Immunol. 1992 Apr 15;141(1):233-42.
PMID: 1555251 [PubMed - indexed for MEDLINE]

103: Ichiba H, Kusuda S, Itagane Y, Fujita K, Issiki G. Links

Measurement of growth promoting activity in human milk using a fetal small intestinal cell line.
Biol Neonate. 1992;61(1):47-53.
PMID: 1567928 [PubMed - indexed for MEDLINE]

104: Iivanainen A, Holtta E, Stahls A, Andersson LC. Links

Colostral growth factors. Possible role in bovine udder epithelial cell regeneration.
Acta Vet Scand. 1992;33(3):197-203.
PMID: 1442366 [PubMed - indexed for MEDLINE]

105: Hooton JW, Pabst HF, Spady DW, Paetkau V. Links

Human colostrum contains an activity that inhibits the production of IL-2.
Clin Exp Immunol. 1991 Dec;86(3):520-4.
PMID: 1836162 [PubMed - indexed for MEDLINE]

106: Riedel-Caspari G, Schmidt FW, Marquardt J. Links

The influence of colostral leukocytes on the immune system of the neonatal calf. IV. Effects on bactericidity, complement and interferon; synopsis.
Dtsch Tierarztl Wochenschr. 1991 Oct;98(10):395-8.
PMID: 1752213 [PubMed - indexed for MEDLINE]

107: Bocci V, von Bremen K, Corradeschi F, Luzzi E, Paulesu L. Links

What is the role of cytokines in human colostrum?
J Biol Regul Homeost Agents. 1991 Oct-Dec;5(4):121-4.
PMID: 1725087 [PubMed - indexed for MEDLINE]

108: Saito S, Maruyama M, Kato Y, Moriyama I, Ichijo M. Links

Detection of IL-6 in human milk and its involvement in IgA production.
J Reprod Immunol. 1991 Sep;20(3):267-76.
PMID: 1960707 [PubMed - indexed for MEDLINE]

109: Sordillo LM, Redmond MJ, Campos M, Warren L, Babiuk LA. Links

Cytokine activity in bovine mammary gland secretions during the periparturient period.
Can J Vet Res. 1991 Jul;55(3):298-301.
PMID: 1716178 [PubMed - indexed for MEDLINE]

110: Bombara CJ, Taylor RL Jr. Links

Signal transduction events in chicken interleukin-1 production.
Poult Sci. 1991 Jun;70(6):1372-80.
PMID: 1653422 [PubMed - indexed for MEDLINE]

111: Lecce JG, Cummins JM, Richards AB. Links

Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha.
Mol Biother. 1990 Dec;2(4):211-6.
PMID: 1963065 [PubMed - indexed for MEDLINE]

112: Neira P. Links

[New treatments for cryptosporidiosis]
Rev Med Chil. 1990 Sep;118(9):1037. Spanish. No abstract available.
PMID: 1983810 [PubMed - indexed for MEDLINE]

113: Nikolova E, Staykova M, Raicheva D, Karadjova M, Neronov A, Ivanov I, Goranov I. Links

Interleukin production by human colostral cells after in vitro mitogen stimulation.
Am J Reprod Immunol. 1990 Aug;23(4):104-6.
PMID: 2278635 [PubMed - indexed for MEDLINE]

114: Bertotto A, Gerli R, Fabietti G, Crupi S, Arcangeli C, Scalise F, Vaccaro R. Links

Human breast milk T lymphocytes display the phenotype and functional characteristics of memory T cells.
Eur J Immunol. 1990 Aug;20(8):1877-80.
PMID: 2120066 [PubMed - indexed for MEDLINE]

115: Munoz C, Endres S, van der Meer J, Schlesinger L, Arevalo M, Dinarello C. Links

Interleukin-1 beta in human colostrum.
Res Immunol. 1990 Jul-Aug;141(6):505-13.
PMID: 2284496 [PubMed - indexed for MEDLINE]

116: Tokuyama H, Tokuyama Y, Migita S. Links

Isolation of two new proteins from bovine colostrum which stimulate

epidermal growth factor-dependent colony formation of NRK-49F cells.
Growth Factors. 1990;3(2):105-14.
PMID: 2206554 [PubMed - indexed for MEDLINE]

117: Rodriguez C, Subiza JL, Mateos P, Casado de Frias E, Moro M, De la Concha EG. Links

Comparative functional study of colostral macrophages from mothers delivering preterm and at term.
Acta Paediatr Scand. 1989 May;78(3):337-41.
PMID: 2787091 [PubMed - indexed for MEDLINE]

118: Chen CC, Hsieh KH, Chen CL. Links

[Immunological study of colostrum]
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1988 Nov;21(4):191-8. Chinese.
PMID: 3267181 [PubMed - indexed for MEDLINE]

119: Julius MH, Janusz M, Lisowski J. Links

A colostral protein that induces the growth and differentiation of resting B lymphocytes.
J Immunol. 1988 Mar 1;140(5):1366-71.
PMID: 3257974 [PubMed - indexed for MEDLINE]

120: Wilson GB, Poindexter C, Fort JD, Ludden KD. Links

De novo initiation of specific cell-mediated immune responsiveness in chickens by transfer factor (specific immunity inducer) obtained from bovine colostrum and milk.
Acta Virol. 1988 Jan;32(1):6-18.
PMID: 2897772 [PubMed - indexed for MEDLINE]

121: Narayan O, Zink MC. Links

Role of macrophages in lentivirus infections.
Adv Vet Sci Comp Med. 1988;32:129-48. Review. No abstract available.
PMID: 2461057 [PubMed - indexed for MEDLINE]

122: Cera K, Mahan DC, Simmen FA. Links

In vitro growth-promoting activity of porcine mammary secretions: initial characterization and relationship to known peptide growth factors.
J Anim Sci. 1987 Oct;65(4):1149-59.
PMID: 3667456 [PubMed - indexed for MEDLINE]

123: Shing Y, Klagsbrun M. Links

Purification and characterization of a bovine colostrum-derived growth factor.
Mol Endocrinol. 1987 May;1(5):335-8.
PMID: 3274892 [PubMed - indexed for MEDLINE]

124: Shing Y, Davidson S, Klagsbrun M. Links

Purification of polypeptide growth factors from milk.
Methods Enzymol. 1987;146:42-8.
PMID: 3500386 [PubMed - indexed for MEDLINE]

125: Sarfati M, Vanderbeeken Y, Rubio-Trujillo M, Duncan D, Delespesse G. Links

Presence of IgE suppressor factors in human colostrum.
Eur J Immunol. 1986 Aug;16(8):1005-8.
PMID: 3743629 [PubMed - indexed for MEDLINE]

126: Collins RA, Oldham G. Links

Proliferative responses and IL-2 production by mononuclear cells from

bovine mammary secretions, and the effect of mammary secretions on peripheral blood lymphocytes.
Immunology. 1986 Aug;58(4):647-51.
PMID: 3488266 [PubMed - indexed for MEDLINE]

127: Komiyama K, Crago SS, Itoh K, Moro I, Mestecky J. Links

Inhibition of natural killer cell activity by IgA.
Cell Immunol. 1986 Aug;101(1):143-55.
PMID: 2427207 [PubMed - indexed for MEDLINE]

128: MacLachlan NJ, Anderson KP. Links

Effect of recombinant DNA-derived bovine alpha-1 interferon on transmissible gastroenteritis virus infection in swine.
Am J Vet Res. 1986 May;47(5):1149-52.
PMID: 3717740 [PubMed - indexed for MEDLINE]

129: Sarfati M, Duncan D, Delespesse G. Links

Production and characterization of rabbit anti-idiotypic antibodies specific to mouse monoclonal anti-human IgE and reacting with IgE-binding factors and lymphocyte receptors for IgE.
Eur J Immunol. 1986 Apr;16(4):325-31.
PMID: 2938966 [PubMed - indexed for MEDLINE]

130: Nair MP, Schwartz SA, Slade HB, Johnson MZ, Quebbeman JF, Beer AE. Links

Comparison of the cellular cytotoxic activities of colostral lymphocytes and maternal peripheral blood lymphocytes.
J Reprod Immunol. 1985 May;7(3):199-213. Review.
PMID: 2410614 [PubMed - indexed for MEDLINE]

131: Roque-Barreira MC, Campos-Neto A. Links

Jacalin: an IgA-binding lectin.
J Immunol. 1985 Mar;134(3):1740-3.
PMID: 3871459 [PubMed - indexed for MEDLINE]

132: Schwers A, Vanden Broecke C, Maenhoudt M, Beduin JM, Werenne J, Pastoret PP. Links

Experimental rotavirus diarrhoea in colostrum-deprived newborn calves: assay of treatment by administration of bacterially produced human interferon (Hu-IFN alpha 2).
Ann Rech Vet. 1985;16(3):213-8.
PMID: 4062197 [PubMed - indexed for MEDLINE]

133: [No authors listed] Links

Growth-promoting factors in mammalian milks.
Nutr Rev. 1984 Nov;42(11):389-91. Review. No abstract available.
PMID: 6396548 [PubMed - indexed for MEDLINE]

134: Shing YW, Klagsbrun M. Links

Human and bovine milk contain different sets of growth factors.
Endocrinology. 1984 Jul;115(1):273-82.
PMID: 6610546 [PubMed - indexed for MEDLINE]

135: Brown KD, Blakeley DM. Links

Partial purification and characterization of a growth factor present in goat's colostrum. Similarities with platelet-derived growth factor.
Biochem J. 1984 Apr 15;219(2):609-17.
PMID: 6378177 [PubMed - indexed for MEDLINE]

136: Noda K, Umeda M, Ono T. Links

Transforming growth factor activity in human colostrum.
Gann. 1984 Feb;75(2):109-12.
PMID: 6329877 [PubMed - indexed for MEDLINE]

137: Vanden Broecke C, Schwers A, Dagenais L, Goossens A, Maenhoudt M, Pastoret PP, Werenne J. Links

Interferon response in colostrum-deprived newborn calves infected with bovine rotavirus: its possible role in the control of the pathogenicity.
Ann Rech Vet. 1984;15(1):29-34.
PMID: 6207759 [PubMed - indexed for MEDLINE]

138: Brown RW, Baetz AL, McDonald TJ. Links

Fractionation of a whey growth factor for Streptococcus agalactiae into two active components containing proteins.
J Dairy Sci. 1983 Nov;66(11):2303-11.
PMID: 6361080 [PubMed - indexed for MEDLINE]

139: Kohl S, Harmon MW, Tang JP. Links

Cytokine-stimulated human natural killer cytotoxicity: response to rotavirus-infected cells.
Pediatr Res. 1983 Nov;17(11):868-72.
PMID: 6316244 [PubMed - indexed for MEDLINE]

140: Sinha SK, Yunis AA. Links

Isolation of colony stimulating factor from human milk.
Biochem Biophys Res Commun. 1983 Jul 29;114(2):797-803.
PMID: 6349636 [PubMed - indexed for MEDLINE]

141: Brown KD, Blakeley DM. Links

Cell growth-promoting activity in mammary secretions of the goat, cow and sheep.
Br Vet J. 1983 Jan-Feb;139(1):68-78. No abstract available.
PMID: 6839120 [PubMed - indexed for MEDLINE]

142: Pahwa A, Mathur BN. Links

Status of 'bifidus growth stimulating factor' of human milk.
Indian J Pediatr. 1982 Nov-Dec;49(401):785-90. No abstract available.
PMID: 7182353 [PubMed - indexed for MEDLINE]

143: Kohl S, Pickering LK, Loo LS. Links

Virus-infected colostral cell cytokine stimulation of human leukocyte natural killer cytotoxicity.
Infect Immun. 1982 May;36(2):691-5.
PMID: 6282758 [PubMed - indexed for MEDLINE]

144: Ballard FJ, Nield MK, Francis GL, Dahlenburg GW, Wallace JC. Links

The relationship between the insulin content and inhibitory effects of bovine colostrum on protein breakdown in cultured cells.
J Cell Physiol. 1982 Mar;110(3):249-54.
PMID: 7045139 [PubMed - indexed for MEDLINE]

145: Ballard FJ, Nield MK, Francis GL, Knowles SE. Links

Regulation of intracellular protein degradation by insulin and growth factors.
Acta Biol Med Ger. 1981;40(10-11):1293-300.
PMID: 6282020 [PubMed - indexed for MEDLINE]

146: Filho JM, De Castro AF, Serafim MB, Gomes AJ. Links

[Heat-labile anti-enterotoxin antibodies to Escherichia coli and anti-colonization factor in human colostrum]
Rev Inst Med Trop Sao Paulo. 1980 Jan-Feb;22(1):7-14. Portuguese. No abstract available.
PMID: 7001605 [PubMed - indexed for MEDLINE]

147: Pitt J. Links

The milk mononuclear phagocyte.
Pediatrics. 1979 Nov;64(5 Pt 2 Suppl):745-9. No abstract available.
PMID: 503697 [PubMed - indexed for MEDLINE]

148: Lawton JW, Shortridge KF, Wong RL, Ng MH. Links

Interferon synthesis by human colostral leucocytes.
Arch Dis Child. 1979 Feb;54(2):127-30.
PMID: 434888 [PubMed - indexed for MEDLINE]

149: Klagsbrun M, Neumann J. Links

The serum-free growth of Balb/c 3T3 cells in medium supplemented with bovine colostrum.
J Supramol Struct. 1979;11(3):349-59.
PMID: 544922 [PubMed - indexed for MEDLINE]

150: Emodi G, Just M. Links

Interferon production by lymphocytes in human milk.
Scand J Immunol. 1974;3(2):157-60. No abstract available.
PMID: 4362733 [PubMed - indexed for MEDLINE]

151: Goldman AS, Smith CW. Links

Host resistance factors in human milk.
J Pediatr. 1973 Jun;82(6):1082-90. Review.
PMID: 4573989 [PubMed - indexed for MEDLINE]

152: Grimmonprez L. Links

[Milk carbohydrates]
Ann Nutr Aliment. 1971;25(2):A39-79. French. No abstract available.
PMID: 5171645 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Items 1-152 of 152 One page.

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Dec 1 2003 07:03:59

h cb h g e e e fcg e ch b e

```
Connecting via Winsock to STN
Welcome to STN International!  Enter x:x
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
* * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:49:33 ON 08 DEC 2003

=> file BIOSCIENCE
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ADISCTI' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 15:49:44 ON 08 DEC 2003

FILE 'ANABSTR' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT 2003 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 15:49:44 ON 08 DEC 2003

FILE 'CAPLUS' ENTERED AT 15:49:44 ON 08 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (c) 2003 DECHEMA eV

FILE 'CEN' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 15:49:44 ON 08 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 ProQuest Information and Learning Company; All Rights Reserved.
```

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 15:49:44 ON 08 DEC 2003

FILE 'FOMAD' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'GENBANK' ENTERED AT 15:49:44 ON 08 DEC 2003

FILE 'HEALSAFE' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 15:49:44 ON 08 DEC 2003

FILE 'NIOSHTIC' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 15:49:44 ON 08 DEC 2003
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.

All rights reserved. (2003)

FILE 'NUTRACEUT' ENTERED AT 15:49:44 ON 08 DEC 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 15:49:44 ON 08 DEC 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 WIPO

FILE 'PHAR' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 15:49:44 ON 08 DEC 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 Prous Science

FILE 'TOXCENTER' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 ACS

FILE 'USPATFULL' ENTERED AT 15:49:44 ON 08 DEC 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:49:44 ON 08 DEC 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'VETU' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 15:49:44 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s colostrinin
 54 FILES SEARCHED...
L1 448 COLOSTRININ

=> DUP REM L1
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L1
L2 375 DUP REM L1 (73 DUPLICATES REMOVED)

=> D L2 1-375

L2 ANSWER 1 OF 375 PHIN COPYRIGHT 2003 PJB on STN

AN 2003:12137 PHIN
DN B00805182
DED 17 Jun 2003
TI Bioventure-View's Stock table highlights - Another two weeks of gains
SO Bioventure-View (2003) No. 1812 p8
DT Newsletter
FS FULL

L2 ANSWER 2 OF 375 IFIPAT COPYRIGHT 2003 IFI on STN DUPLICATE 1
AN 10347192 IFIPAT;IFIUDB;IFICDB
TI USE OF ***COLOSTRININ*** , CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF, AS OXIDATIVE STRESS REGULATORS
IN Boldogh Istvan; Hughes Thomas K JR; Stanton G John
PA Texas, University of System (83960)
PI US 2003091606 A1 20030515
AI US 2002-281652 20021028
RLI US 2000-641803 20000817 DIVISION 6500798
PRAI US 1999-149310P 19990817 (Provisional)
FI US 2003091606 20030515
US 6500798
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 61
GI 7 Figure(s).

FIG. 1. Principle of 2'7'-dihydro-dichlorofluorescein-diacetate assay. Chemical structure of H2DCF-DA, H2DCF and DCF (A). Uptake of H2DCF-DA and fate of intracellular H2DCF (B). Histogram: a change in DCF-mediated fluorescence intensity after treatment of H2DCF-loaded cells with 50 mu M H2O2 (C).

FIG. 2. Cell cycle stage distribution of logaritmically replicating PC12 (A) and ECV304 (B) cell culture. Cells at approximately 70% confluence were harvested and prepared for cell cycle analysis. DNA content of cells was determined by flow cytometry. Each data points represent the mean fluorescence for 10,000 cells. Statistical analysis was carried out using ModFitLT V2.0 software.

FIG. 3. Change in DCF fluorescence intensity as function of time, after addition of H2O2 or TPA to PC12 cells. Cells (106) were loaded with H2DCF-DA (2.5 micromolar (greater-than tM)) for 12 minutes (min) and increasing concentrations of H2O2 (0, 12.5, 25 50 and 100 mu M) or TPA (0, 50, 100, and 200 nanograms per milliliter (ng/ml)) was added. Fluorescence intensities were determined at 0, 5, 10 and 15 minutes after addition of H2O2 or TPA addition. Each data point represents the mean fluorescence for 10,000 cells.

FIG. 4. Effect of N-acetyl-L-cysteine, butylated hydroxyanisole, and catalase on H2,2-induced H2DCF oxidation. Treated and nontreated cells, loaded with H2DCF-DA (2.5 mu M) were exposed to 25 mu M H2O2 and changes in fluorescence intensities were determined at 0 and 15 min by flow cytometry. Each data points represent the mean fluorescence for 10,000 cells.

FIG. 5. Effect of colostrum, ***colostrinin*** , and its constituent peptides. Cells were H2DCF-DA loaded and treated with compounds as described in the Examples Section. Changes in fluorescence intensity of treated and mock-treated cell cultures were determined as a function time (0, 5, 10, 15 minutes) after addition of 25 mu M H2O2. The concentrations of colostrum ***colostrinin*** , and its constituent peptides were 10 micrograms per milliliter (mu g/ml). Each data points represent the mean fluorescence for 10,000 cells.

FIG. 6. Reduction in TPA-induced reactive oxidizing species (ROS) levels in the presence of colostrum, ***colostrinin*** , and its constituent peptides as a function of time. Cells were H2DCF-DA loaded and treated with compounds as described in the Examples Section. Changes in fluorescence intensity of treated and mocktreated cell cultures were determined as a function time (0, 5, 10, 15 minutes) after addition of 100 nanograms (ng) TPA. The concentrations of colostrum, ***colostrinin*** , and its constituent peptides were 10 mu g/ml. Each data points represent the mean fluorescence for 10,000 cells.

FIG. 7. Reduction in ROS levels by colostrum, colostrin, and its constituent peptides from three independent experiments. H2DCFDA-loaded cells were treated with compounds as described in the Examples Section. Changes in fluorescence intensity of treated and mock-treated cell cultures were determined as a function time (0, 5, 10, 15 minutes) after addition of 100 ng TPA. The concentrations of colostrum, ***colostrinin*** , and its constituent peptides were 10 mu g/ml. Each data points represent the mean fluorescence for 10,000 cells.

L2 ANSWER 3 OF 375 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:887447 CAPLUS
TI A Proline-Rich Polypeptide Complex (PRP) from Ovine Colostrum. Studies on the Effect of PRP on Nitric Oxide (NO) Production Induced by LPS in THP-1 Cells
AU Mikulska, Joanna Elzbieta; Lisowski, Jozef
CS Institute of Immunology and Experimental Therapy, Department of Immunochemistry, Polish Academy of Sciences, Wroclaw, Pol.
SO Immunopharmacology and Immunotoxicology (2003), 25(4), 645-654
CODEN: IITOEF; ISSN: 0892-3973
PB Marcel Dekker, Inc.
DT Journal
LA English

L2 ANSWER 4 OF 375 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 2
AN 2003:404201 BIOSIS
DN PREV200300404201
TI Modulation of 4HNE-mediated signaling by proline-rich peptides from ovine colostrum.
AU Boldogh, Istvan; Liebenthal, Daniel; Hughes, T. Kley; Juelich, Terry L.; Georgiades, Jerzy A.; Kruzel, Marian L.; Stanton, G. John [Reprint Author]
CS Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, 77555, USA
jstanton@utmb.edu
SO Journal of Molecular Neuroscience, (April 2003) Vol. 20, No. 2, pp. 125-134. print.
ISSN: 0895-8696 (ISSN online).
DT Article
LA English
ED Entered STN: 3 Sep 2003
Last Updated on STN: 3 Sep 2003

L2 ANSWER 5 OF 375 ADISCTI COPYRIGHT (C) 2003 Adis Data Information BV on STN
AN 2003:6869 ADISCTI
DN 809026793
TI ColostrininTM Clinical Study to be published in Journal of Alzheimer's Disease.
ADIS TITLE: ***Colostrinin*** : therapeutic use.
Alzheimer's disease.
AU ReGen Therapeutics Plc.
CS ReGen Therapeutics.
SO Media Release (Oct 8, 2003)
DT Study
RE Alzheimer's Disease and Cognition Disorders| Neurological Disorders
FS Summary
LA English
WC 258

L2 ANSWER 6 OF 375 IMSDRUGNEWS COPYRIGHT 2003 IMSWORLD on STN

ACCESSION NUMBER: 2002:2185 IMSDRUGNEWS
TITLE: ***COLOSTRININ*** ReGen Therapeutics clinical data
SOURCE: R&D Focus Drug News (15 Jul 2002).
WORD COUNT: 163

L2 ANSWER 7 OF 375 PHIN COPYRIGHT 2003 PJB on STN

AN 2002:9902 PHIN
DN S00754556
DED 15 May 2002
TI Renewed hope for ReGen's AD (Alzheimer's disease) drug
SO Scrip (2002) No. 2746 p27
DT Newsletter
FS FULL

L2 ANSWER 8 OF 375 PHIN COPYRIGHT 2003 PJB on STN

AN 2002:10478 PHIN
DN S00755020
DED 15 May 2002
TI Drug options for Alzheimer's despite failures
SO Scrip (2002) No. 2746 p27
DT Newsletter

FS FULL

L2 ANSWER 9 OF 375 PHIN COPYRIGHT 2003 PJB on STN

AN 2002:8252 PHIN
DN S00750442
DED 10 Apr 2002
TI Prana up on Alzheimer's results
SO Scrip (2002) No. 2736 p22
DT Newsletter
FS FULL

L2 ANSWER 10 OF 375 PHIN COPYRIGHT 2003 PJB on STN

AN 2002:7482 PHIN
DN S00749096
DED 27 Mar 2002
TI Disappointment for ReGen's AD (Alzheimer's disease) drug
SO Scrip (2002) No. 2732 p20
DT Newsletter
FS FULL

L2 ANSWER 11 OF 375 PHIN COPYRIGHT 2003 PJB on STN

AN 2002:14124 PHIN
DN S00762244
DED 10 Jul 2002
TI ReGen plans more trials of AD (Alzheimer's disease) drug
SO Scrip (2002) No. 2762 p19
DT Newsletter
FS FULL

L2 ANSWER 12 OF 375 PHIN COPYRIGHT 2003 PJB on STN

AN 2002:15053 PHIN
DN B00764280
DED 23 Jul 2002
TI Bioventure-View Stock Table Highlights - Amgen increases its lead over US biotech
SO Bioventure-View (2002) No. 1715 p8
DT Newsletter
FS FULL

L2 ANSWER 13 OF 375 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 2002:395152 PROMT
TITLE: BVV stock table highlights. (Commentary).(Brief Article)
AUTHOR(S): Blades, Victoria
SOURCE: BioVenture View, (23 Jul 2002) Vol. 17, No. 15, pp. 8(2).
ISSN: ISSN: 0892-1903.
PUBLISHER: Pharmabooks Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1535
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L2 ANSWER 14 OF 375 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 2002:551037 PROMT
TITLE: Biotech firms flounder in new year. (Biotechnology).(Brief Article)
SOURCE: Chemistry and Industry, (1 Apr 2002) pp. 4(1).
ISSN: ISSN: 0009-3068.
PUBLISHER: Society of Chemical Industry
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 414
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L2 ANSWER 15 OF 375 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 2002:572265 PROMT
TITLE: Bruised investors flock to short but attractive Man.(City)
AUTHOR(S): Jackson; Proes, Alex
SOURCE: Daily Telegraph (London, England), (9 Jul 2002) .
ISSN: ISSN: 0307-1235.

PUBLISHER: Telegraph Group Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 917
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L2 ANSWER 16 OF 375 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 2002:574095 PROMT
TITLE: ReGen announces successful trial of Alzheimer's disease treatment.(Brief Article)
SOURCE: M2 Europharma, (15 Jul 2002) .
PUBLISHER: M2 Communications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 199
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L2 ANSWER 17 OF 375 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 2002:359512 PROMT
TITLE: ***COLOSTRININ*** ReGen Therapeutics clinical data.(Brief Article)
SOURCE: R & D Focus Drug News, (15 Jul 2002) .
ISSN: ISSN: 1350-1135.
PUBLISHER: IMSworld Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 173
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L2 ANSWER 18 OF 375 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 2002:260387 PROMT
TITLE: ReGen Alzheimer's drug effective in AD.(Alzheimer's disease therapy from ReGen Therapeutics)(Brief Article)
SOURCE: Marketletter, (13 May 2002) .
ISSN: ISSN: 0951-3175.
PUBLISHER: Marketletter Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 89
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L2 ANSWER 19 OF 375 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 2002:361942 PROMT
TITLE: ReGen lifted on 30-week ***Colostrinin*** data.(Alzheimer's disease drug shows positive signs in phase II testing)(Brief Article)
SOURCE: Marketletter, (15 Jul 2002) .
ISSN: ISSN: 0951-3175.
PUBLISHER: Marketletter Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 241
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L2 ANSWER 20 OF 375 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 3
AN 2003:86005 BIOSIS
DN PREV200300086005
TI Use of ***colostrinin*** , constituent peptides thereof, and analogs thereof, as oxidative stress regulators.
AU Stanton, G. John [Inventor, Reprint Author]; Hughes, Thomas K. Jr. [Inventor]; Boldogh, Istvan [Inventor]
CS Texas City, TX, USA
ASSIGNEE: Board of Regents, The University of Texas System
PI US 6500798 December 31, 2002
SO Official Gazette of the United States Patent and Trademark Office Patents, (Dec. 31, 2002) Vol. 1265, No. 5. http://www.uspto.gov/web/menu/patdata.html. e-file.
ISSN: 0098-1133 (ISSN print).
DT Patent
LA English
ED Entered STN: 6 Feb 2003

Last Updated on STN: 6 Feb 2003

L2 ANSWER 21 OF 375 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT/ISI on STN
AN 2003-01922 BIOTECHDS
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive;
vector-mediated gene transfer and expression in host cell for recombinant protein production and disease therapy
AU GEORGIADES J A
PA REGEN THERAPEUTICS PLC
PI WO 2002046211 13 Jun 2002
AI WO 2001-GB5376 5 Dec 2001
PRAI GB 2000-29777 6 Dec 2000; GB 2000-29777 6 Dec 2000
DT Patent
LA English
OS WPI: 2002-619016 [66]

L2 ANSWER 22 OF 375 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 5
AN 2002:142541 CAPLUS
DN 136:194259
TI Use of ***colostrinin*** , constituent peptides thereof, and analogs thereof to promote neural cell differentiation
IN Boldogh, Istvan; Stanton, John G.; Hughes, Thomas K., Jr.
PA The University of Texas System, USA
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002013851	A1	20020221	WO 2000-US22777	20000817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000069179	A5	20020225	AU 2000-69179	20000817
PRAI WO 2000-US22777	A	20000817		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 23 OF 375 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 6
AN 2002:142540 CAPLUS
DN 136:194274
TI Use of ***colostrinin*** , constituent peptides thereof, and analogs thereof as oxidative stress regulators
IN Stanton, G. John; Hughes, Thomas K., Jr.; Boldogh, Istvan
PA The University of Texas System, USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002013850	A1	20020221	WO 2000-US22776	20000817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000069178	A5	20020225	AU 2000-69178	20000817
PRAI WO 2000-US22776	A	20000817		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 24 OF 375 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 7
AN 2002:142539 CAPLUS
DN 136:194245
TI Use of ***colostrinin*** , constituent peptides thereof, and analogs thereof for inducing cytokines
IN Stanton, G. John; Hughes, Thomas K., Jr.; Boldogh, Istvan; Georgiades, Jerzy
PA The University of Texas System, USA; Regen Therapeutics PLC
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002013849	A1	20020221	WO 2000-US22775	20000817

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2000067883	A5	20020225	AU 2000-67883	20000817
PRAI WO 2000-US22775	A	20000817		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 25 OF 375 USPATFULL on STN DUPLICATE 8
AN 2002:8076 USPATFULL
TI Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
IN Gohlke, Marcus B., Houston, TX, UNITED STATES
Cockrum, Richard H., Perry, IA, UNITED STATES

PI	US 2002004073	A1	20020110
	US 6475511	B2	20021105
AI	US 2001-945997	A1	20010904 (9)

RLI Division of Ser. No. US 2001-778294, filed on 6 Feb 2001, PENDING
Division of Ser. No. US 1999-370654, filed on 6 Aug 1999, GRANTED, Pat. No. US 6258383
PRAI US 1998-96697P 19980814 (60)
DT Utility
FS APPLICATION
LN.CNT 871
INCL INCLM: 424/535.000
INCLS: 514/002.000
NCL NCLM: 424/441.000
NCLS: 424/440.000; 424/464.000; 424/535.000; 424/736.000
IC [7]
ICM: A61K035-20
ICS: A61K038-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 26 OF 375 FSTA COPYRIGHT 2003 IFIS on STN
AN 2003:G0079 FSTA
TI Peptide fragments of ***colostrinin*** and their use.
IN Georgiades, J. A.
PA Regen Therapeutics plc; Regen Therapeutics, London W1W 8SA, UK
SO UK Patent Application, (2002)
PI GB 2374871 A
PRAI GB 2001-217327 20010126
DT Patent
LA English

L2 ANSWER 27 OF 375 USPATFULL on STN
AN 2002:329521 USPATFULL
TI Dietary supplement comprising lactoferrin and citrus pectin
IN Gohlke, Marcus B., Houston, TX, UNITED STATES
Cockrum, Richard H., Perry, IA, UNITED STATES
PA Lactoferrin Products Company (U.S. corporation)

PI	US 2002187200	A1	20021212
AI	US 2002-209546	A1	20020731 (10)

RLI Division of Ser. No. US 2001-945997, filed on 4 Sep 2001, PENDING

Division of Ser. No. US 2001-778294, filed on 6 Feb 2001, GRANTED, Pat. No. US 6410058 Division of Ser. No. US 1999-370654, filed on 6 Aug 1999, GRANTED, Pat. No. US 6258383
PRAI US 1998-96697P 19980814 (60)
DT Utility
FS APPLICATION
LN.CNT 871
INCL INCLM: 424/535.000
INCLS: 424/736.000
NCL NCLM: 424/535.000
NCLS: 424/736.000
IC [7]
ICM: A61K035-20
ICS: A61K035-78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 28 OF 375 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2002156940 EMBASE
TI Advances in the development of A.beta.-related therapeutic strategies for Alzheimer's disease.
AU Barrow C.J.
CS Dr. C.J. Barrow, Department of Research/Development, Ocean Nutrition Canada, Halifax, NS, Canada
SO Drug News and Perspectives, (2002) 15/2 (102-109).
Refs: 91
ISSN: 0214-0934 CODEN: DNPEED
CY Spain
DT Journal; General Review
FS 008 Neurology and Neurosurgery
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English

L2 ANSWER 29 OF 375 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 9
AN 2002:907426 CAPLUS
DN 137:379957
TI ***Colostrinin*** proline-rich polypeptide complex from ovine colostrum - a long-term study of its efficacy in Alzheimer's disease
AU Leszek, Jerzy; Inglot, Anna D.; Janusz, Maria; Byczkiewicz, Franciszek; Kiejna, Andrzej; Georgiades, Jerzy; Lisowski, Jozef
CS Department of Psychiatry, Medical University, Wroclaw, Pol.
SO Medical Science Monitor (2002), 8(10), PI93-PI96
CODEN: MSMOFR; ISSN: 1234-1010
PB International Scientific Literature, Inc.
DT Journal
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 30 OF 375 CIN COPYRIGHT 2003 ACS on STN
AN 31(15):16562K CIN
TI Clinical results
SO BioCentury, 25 Mar 2002 (20020325), 10(13, Pt. 2), p. B15-B16. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L2 ANSWER 31 OF 375 CIN COPYRIGHT 2003 ACS on STN
AN 31(31):31186J CIN
TI Clinical results
SO BioCentury, 15 Jul 2002 (20020715), 10(31, Pt. 2), p. B11-B12. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L2 ANSWER 32 OF 375 CIN COPYRIGHT 2003 ACS on STN
AN 31(17):19042B CIN
TI ReGen shares dive on trial data for its sole drug
SO Wall St. J. Eur., 25 Mar 2002 (20020325), p. A10. ISSN: 0921-9986; CODEN: WSJEAJ.
LA English

L2 ANSWER 33 OF 375 PHIN COPYRIGHT 2003 PJB on STN

AN 2001:20672 PHIN
DN S00731462
DED 2 Nov 2001
TI ReGen updates on AD (Alzheimer's disease) therapy
SO Scrip (2001) No. 2692 p27
DT Newsletter
FS FULL

L2 ANSWER 34 OF 375 PHIN COPYRIGHT 2003 PJB on STN

AN 2001:13478 PHIN
DN S00717136
DED 11 Jul 2001
TI ReGen takes on Alzheimer's
SO Scrip (2001) No. 2659 p20
DT Newsletter
FS FULL

L2 ANSWER 35 OF 375 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 2001:452263 PROMT
TITLE: The miracle worker.(Business Review)(includes corporate history)(ReGen Therapeutics Chief Executive Mike Harvey)
AUTHOR(S): Wheatley, Catherine
SOURCE: The Independent, (6 Jun 2001) pp. BR3(1).
ISSN: 0951-9467.
PUBLISHER: Newspaper Publishing Plc (UK)
DOCUMENT TYPE: Newsletter
LANGUAGE: English

L2 ANSWER 36 OF 375 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 2001:308789 PROMT
TITLE: ReGen's ***Colostrinin*** trials continue.(Brief Article)
SOURCE: Marketletter, (23 Apr 2001) .
ISSN: 0951-3175.
PUBLISHER: Marketletter Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 204
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L2 ANSWER 37 OF 375 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 2001:143711 PROMT
TITLE: EUROPEAN PATENT DISCLOSURES.(Brief Article)
SOURCE: BIOWORLD Today, (20 Feb 2001) Vol. 12, No. 34.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 2190
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L2 ANSWER 38 OF 375 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 10
AN 2001:565091 CAPLUS
DN 135:132472
TI Peptide fragments of ***colostrinin*** and their therapeutic and food additive use
IN Georgiades, Jerzy Alexander
PA Regen Therapeutics PLC, UK
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001055199	A1	20010802	WO 2001-GB329	20010126

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1250354 A1 20021023 EP 2001-902493 20010126

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

GB 2374871 A1 20021030 GB 2002-17327 20010126

PRAI GB 2000-1825 A 20000126

WO 2001-GB329 W 20010126

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 39 OF 375 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 11

AN 2001:137235 CAPLUS

DN 134:188221

TI Use of ***colostrinin*** , constituent peptides, and analogs to promote neural cell differentiation

IN Boldogh, Istvan

PA The University of Texas System, USA

SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012651	A2	20010222	WO 2000-US22774	20000817
	WO 2001012651	A3	20020711		
	WO 2001012651	C2	20020912		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	AU 2000069177	A5	20010313	AU 2000-69177	20000817
	EP 1238058	A2	20020911	EP 2000-957579	20000817

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

PRAI	US 1999-149633P	P	19990817		
	WO 2000-US22774	W	20000817		

L2 ANSWER 40 OF 375 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 12

AN 2001:137234 CAPLUS

DN 134:188229

TI Use of ***colostrinin*** , constituent peptides, and analogs as oxidative stress regulators

IN Stanton, G. John; Hughes, Thomas K., Jr.; Boldogh, Istvan

PA The University of Texas System, USA

SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012650	A2	20010222	WO 2000-US22665	20000817

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	AU 2000070617	A5	20010313	AU 2000-70617	20000817
	US 6500798	B1	20021231	US 2000-641803	20000817
	US 2003091606	A1	20030515	US 2002-281652	20021028
PRAI	US 1999-149310P	P	19990817		
	US 2000-641803	A3	20000817		
	WO 2000-US22665	W	20000817		

L2 ANSWER 41 OF 375 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 13

AN 2001:136927 CAPLUS
DN 134:188199
TI Use of ***colostrinin*** , constituent peptides, and analogs for inducing cytokines and as blood cell regulators
IN Stanton, G. John; Hughes, Thomas K., Jr.; Boldogh, Istvan; Georgiades, Jerzy
PA The University of Texas System, USA; Regen Therapeutics PLC
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001011937	A2	20010222	WO 2000-US22818	20000817
	WO 2001011937	A3	20010907		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IS, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2000069197	A5	20010313	AU 2000-69197	20000817
	EP 1224217	A2	20020724	EP 2000-957601	20000817
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI	US 1999-149311P	P	19990817		
	WO 2000-US22818	W	20000817		

L2 ANSWER 42 OF 375 USPATFULL on STN DUPLICATE 14
AN 2001:119060 USPATFULL
TI Methods of use for dietary compositions comprising lactoferrin and colostrum
IN Gohlke, Marcus B., Houston, TX, United States
Cockrum, Richard H., Perry, IA, United States
PA Lactoferrin Products Company. (U.S. corporation)
PI US 2001009681 A1 20010726
US 6410058 B2 20020625
AI US 2001-778294 A1 20010206 (9)
RLI Division of Ser. No. US 1999-370654, filed on 6 Aug 1999, PENDING
PRAI US 1998-96697P 19980814 (60)
DT Utility
FS APPLICATION
LN.CNT 871
INCL INCLM: 424/535.000
NCL NCLM: 424/535.000
NCLS: 424/440.000; 424/441.000; 424/464.000; 424/736.000
IC [7]
ICM: A61K035-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 43 OF 375 USPATFULL on STN
AN 2001:107469 USPATFULL
TI Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
IN Gohlke, Marcus B., Houston, TX, United States
Cockrum, Richard H., Perry, IA, United States
PA Lactoferrin Products Company, Houston, TX, United States (U.S. corporation)
PI US 6258383 B1 20010710
AI US 1999-370654 19990806 (9)
DT Utility
FS GRANTED
LN.CNT 795
INCL INCLM: 424/535.000
INCLS: 454/195.100; 454/440.000; 454/441.000
NCL NCLM: 424/535.000
NCLS: 424/048.000; 424/440.000; 424/441.000; 424/736.000; 514/054.000
IC [7]
ICM: A61K035-20
ICS: A61K035-78; A61K009-20
EXF 424/535; 424/195.1; 424/441; 424/440
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 44 OF 375 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 15
AN 2002:54643 BIOSIS
DN PREV200200054643
TI Milking nature for Alzheimer's treatment.
AU Owens, Joanna
CS E-mail,
Joanna.Owens@drugdiscoverytoday.com
SO Drug Discovery Today, (1st September, 2001) Vol. 6, No. 17, pp. 866-868.
print.
ISSN: 1359-6446.
DT Article
LA English
ED Entered STN: 9 Jan 2002
Last Updated on STN: 25 Feb 2002

L2 ANSWER 45 OF 375 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 16
AN 2002:173419 BIOSIS
DN PREV200200173419
TI Towards an understanding of biological role of ***colostrinin***
peptides.
AU Kruzel, Marian L.; Janusz, Maria; Lisowski, Jozef; Fischleigh, Robert V.;
Georgiades, Jerzy A. [Reprint author]
CS ReGen Therapeutics Plc., London, UK
jerzygeorgiades@msn.com
SO Journal of Molecular Neuroscience, (December, 2001) Vol. 17, No. 3, pp.
379-389. print.
CODEN: JMNEES. ISSN: 0895-8696.
DT Article
LA English
ED Entered STN: 5 Mar 2002
Last Updated on STN: 5 Mar 2002

L2 ANSWER 46 OF 375 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 17
AN 2001:89229 BIOSIS
DN PREV200100089229
TI Cognitive effects of Colostral-Val nonapeptide in aged rats.
AU Popik, Piotr [Reprint author]; Galoch, Zdzislaw; Janusz, Maria; Lisowski,
Jozef; Vetulani, Jerzy
CS Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street,
31-343, Krakow, Poland
nfpopik@cyf-kr.edu.pl
SO Behavioural Brain Research, (29 January, 2001) Vol. 118, No. 2, pp.
201-208. print.
CODEN: BBREDI. ISSN: 0166-4328.
DT Article
LA English
ED Entered STN: 14 Feb 2001
Last Updated on STN: 12 Feb 2002

L2 ANSWER 47 OF 375 MEDLINE on STN
AN 2002062025 MEDLINE
DN 21645236 PubMed ID: 11787957
TI ***Colostrinin*** and ***colostrinin*** -derived nonapeptide
(colostral-val nonapeptide, CVNP) facilitate learning and memory in rats.
AU Popik P
CS Institute of Pharmacology, Polish Academy of Sciences, Krakow..
nfpopik@cyf-kr.edu.pl
SO POLISH JOURNAL OF PHARMACOLOGY, (2001 Mar-Apr) 53 (2) 166-8.
Journal code: 9313882. ISSN: 1230-6002.
CY Poland
DT (LECTURES)
LA English
FS Priority Journals
EM 200207
ED Entered STN: 20020125
Last Updated on STN: 20020702
Entered Medline: 20020701

L2 ANSWER 48 OF 375 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2002:298997 BIOSIS
DN PREV200200298997
TI The Tenth Days of Neuropsychopharmacology, Ustron-Jaszowiec, May 28-30,

2001.
AU Anonymous
SO Polish Journal of Pharmacology, (March-April, 2001) Vol. 53, No. 2, pp. 165-196. print.
Meeting Info.: The Tenth Days of Neuropsychopharmacology. Ustron-Jaszowiec, Poland. May 28-30, 2001.
ISSN: 1230-6002.
DT Conference; (Meeting)
Conference; (Meeting Summary)
LA English
ED Entered STN: 22 May 2002
Last Updated on STN: 22 May 2002

L2 ANSWER 49 OF 375 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2001412978 EMBASE
TI ***Colostrinin*** .
SO Journal of Dementia Care, (2001) 9/6 (37).
ISSN: 1351-8372 CODEN: JDCOA4
CY United Kingdom
DT Journal; Note
FS 008 Neurology and Neurosurgery
030 Pharmacology
032 Psychiatry
037 Drug Literature Index
LA English

L2 ANSWER 50 OF 375 CIN COPYRIGHT 2003 ACS on STN
AN 30(46):48494K CIN
TI Clinical Status
SO BioCentury, 29 Oct 2001 (20011029), 9(48, Pt. 2), p. B16. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L2 ANSWER 51 OF 375 CIN COPYRIGHT 2003 ACS on STN
AN 30(18):17689Y CIN
TI Clinical Status
SO BioCentury, 16 Apr 2001 (20010416), 9(18, Pt. 2), p. B11. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L2 ANSWER 52 OF 375 CIN COPYRIGHT 2003 ACS on STN
AN 30(47):50087Y CIN
TI Deals
SO BioCentury, 5 Nov 2001 (20011105), 9(49, Pt. 2), p. B6. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L2 ANSWER 53 OF 375 IMSDRUGNEWS COPYRIGHT 2003 IMSWORLD on STN DUPLICATE 18

ACCESSION NUMBER: 2000:791 IMSDRUGNEWS
TITLE: ***COLOSTRININ*** ReGen Therapeutics continues investigation
SOURCE: R&D Focus Drug News (28 Feb 2000).
WORD COUNT: 97

L2 ANSWER 54 OF 375 PHIN COPYRIGHT 2003 PJB on STN

AN 2000:4891 PHIN
DN B00656326
DED 1 Mar 2000
TI Small But Not Forgotten - UK Biotechs Trading on OFEX
SO Bioventure-View (2000) No. 1503 p1
DT Newsletter
FS FULL

L2 ANSWER 55 OF 375 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 2000:143899 PROMT
TITLE: UK: REGEN TO JOIN ALTERNATIVE INVESTMENT MARKET.(Brief Article)
SOURCE: Daily Telegraph, (27 Jan 2000) pp. 36.
ISSN: 0307-1235.
PUBLISHER: Telegraph Group Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English

L2 ANSWER 56 OF 375 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 2000:210514 PROMT
TITLE: UK Biotechs trading on OFEX.
AUTHOR(S): Scrivens, John
SOURCE: BioVenture View, (March 2000) Vol. 15, No. 3, pp. 1. ISSN: 0892-1903.
PUBLISHER: BioVenture Publishing
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 2753
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L2 ANSWER 57 OF 375 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT/ISI on STN
AN 2001-04450 BIOTECHDS
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system, viral and bacterial infections, and diseases characterized by amyloid plaques;
vector-mediated gene transfer, expression in host cell and antibody for recombinant protein production and disease therapy and diagnosis
AU Georgiades J A
PA Regen-Therapeutics
LO London, UK.
PI WO 2000075173 14 Dec 2000
AI WO 2000-GB2128 2 Jun 2000
PRAI GB 1999-12852 2 Jun 1999
DT Patent
LA English
OS WPI: 2001-071058 [08]

L2 ANSWER 58 OF 375 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2000228223 EMBASE
TI Drug treatment in dementia.
AU Byrne G.J.
CS G.J. Byrne, University of Queensland, Mental Health Centre, Royal Brisbane Hospital, Herston, QLD 4029, Australia. g.byrne@psychiatry.uq.edu.au
SO Current Opinion in Psychiatry, (2000) 13/4 (415-421).
Refs: 62
ISSN: 0951-7367 CODEN: COPPE8
CY United Kingdom
DT Journal; General Review
FS 008 Neurology and Neurosurgery
030 Pharmacology
032 Psychiatry
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English

L2 ANSWER 59 OF 375 ADISCTI COPYRIGHT (C) 2003 Adis Data Information BV on STN
AN 2000:26729 ADISCTI
DN 800847528
TI ***Colostrinin*** - a polypeptide isolated from early milk, for treatment of Alzheimer's disease.
AU Leszek J; Inglot A D; Janusz M; Lisowski J; Kiejna A; et al.
SO European Neuropsychopharmacology (Sep 1, 2000), Vol. 10 (Suppl. 3), pp. 364
DT Citation
RE Alzheimer's Disease and Cognition Disorders| Neurological Disorders
FS Citation
LA English

L2 ANSWER 60 OF 375 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:542461 BIOSIS
DN PREV200000542461
TI ***Colostrinin*** : A polypeptide isolated from early milk, for treatment of Alzheimer's disease.
AU Leszek, J. [Reprint author]; Inglot, A. D.; Janusz, M.; Lisowski, J.; Kiejna, A. [Reprint author]; Georgiades, J.
CS Clinic of Psychiatry, University of Wroclaw, Wroclaw, Poland
SO European Neuropsychopharmacology, (September, 2000) Vol. 10, No. Supplement 3, pp. S364. print.

Meeting Info.: 13th Congress of the European College of Neuropsychopharmacology. Munich, Germany. September 09-13, 2000.
ISSN: 0924-977X.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English
ED Entered STN: 13 Dec 2000
Last Updated on STN: 11 Jan 2002

L2 ANSWER 61 OF 375 DRUGU COPYRIGHT 2003 THOMSON DERWENT on STN
AN 2001-02609 DRUGU T S
TI ***Colostrinin*** - a polypeptide isolated from early milk, for treatment of Alzheimer's disease.
AU Leszek J; Inglot A D; Janusz M; Lisowski J; Kiejna A; Georgiades J
CS Univ.Wroclaw
LO Wroclaw, Pol.; London, U.K.
SO Eur.Neuropsychopharmacol. (10, Suppl. 3, S364, 2000) 2 Ref.
CODEN: EURNE8 ISSN: 0924-977X
AV University of Wroclaw, Clinic of Psychiatry, Wroclaw, Poland.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L2 ANSWER 62 OF 375 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 20
AN 1999:811039 CAPLUS
DN 132:35067
TI Dietary supplement containing ***colostrinin*** , lactoferrin, and selenium
IN Georgiades, Jerzy A.
PA Regen Biotech Limited, UK
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9965329	A2	19991223	WO 1999-GB1878	19990615
WO 9965329	A3	20000713		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9943787	A1	20000105	AU 1999-43787	19990615
GB 2354153	A1	20010321	GB 2001-1051	19990615
GB 2354153	B2	20021016		
PRAI GB 1998-13031	A	19980616		
WO 1999-GB1878	W	19990615		

L2 ANSWER 63 OF 375 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN DUPLICATE 21
AN 2000:162385 BIOSIS
DN PREV200000162385
TI ***Colostrinin*** (R): A proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study.
AU Leszek, Jerzy; Inglot, Anna D.; Janusz, Maria [Reprint author]; Lisowski, Jozef; Krukowska, Katarzyna; Georgiades, Jerzy A.
CS Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114, Wroclaw, Poland
SO Archivum Immunologiae et Therapiae Experimentalis, (1999) Vol. 47, No. 6, pp. 377-385. print.
CODEN: AITEAT. ISSN: 0004-069X.
DT Article
LA English
ED Entered STN: 26 Apr 2000
Last Updated on STN: 4 Jan 2002

L2 ANSWER 64 OF 375 ADISCTI COPYRIGHT (C) 2003 Adis Data Information BV on

STN
AN 1999:28924 ADISCTI
DN 800741417
TI ***Colostrinin*** : new treatment perspectives of Alzheimer's disease.
ADIS TITLE: ***Colostrinin*** vs selenium: therapeutic use.
Alzheimer's disease.
AU Leszek J W; Inglot A D; Lisowski J; Janusz M; Kieima A; et al.
CS University of Wroclaw, Wroclaw, Poland.
SO American Psychiatric Association 1999 Annual Meeting : New Research Program & Abstracts (May 15, 1999), pp. 216
DT Study
RE Alzheimer's Disease and Cognition Disorders| Neurological Disorders
FS Summary
LA English
WC 313

L2 ANSWER 65 OF 375 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 22
AN 1999:454538 BIOSIS
DN PREV199900454538
TI ***Colostrinin*** , a polypeptide isolated from early milk, facilitates learning and memory in rats.
AU Popik, Piotr [Reprint author]; Bobula, Bartosz; Janusz, Maria; Lisowski, Jozef; Vetulani, Jerzy
CS Institute of Pharmacology, Department of Biochemistry, Polish Academy of Sciences, 12 Smetna Street, 31-343, Krakow, Poland
SO Pharmacology Biochemistry and Behavior, (Sept., 1999) Vol. 64, No. 1, pp. 183-189. print.
CODEN: PBBHAU. ISSN: 0091-3057.
DT Article
LA English
ED Entered STN: 1 Nov 1999
Last Updated on STN: 3 May 2000

L2 ANSWER 66 OF 375 PHIN COPYRIGHT 2003 PJB on STN

AN 1998:19094 PHIN
DN S00599212
DED 21 Oct 1998
TI ReGen raises funds to target Alzheimer's
SO Scrip (1998) No. 2380 p11
DT Newsletter
FS FULL

L2 ANSWER 67 OF 375 PHIN COPYRIGHT 2003 PJB on STN

AN 1998:19156 PHIN
DN S00600856
DED 30 Oct 1998
TI PHARMAPROJECTS - New Neurological Products for week ending 30 October 1998
SO Scrip-Online-plus (1998)
DT Newsletter
FS FULL

L2 ANSWER 68 OF 375 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 1998:332523 PROMT
TITLE: ReGen Looking To Raise L2.5 Million
SOURCE: Marketletter, (6 Jul 1998) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 167
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L2 ANSWER 69 OF 375 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 1998:361913 PROMT
TITLE: ReGen sesks 2.5m backing
Looks for GBP2.5 mil in funding from the City following tests using Alzheimer's disease drug ***Colostrinin*** developed in Poland
SOURCE: The Times, (13 Jul 1998) pp. 45.
ISSN: 0140-0460.
LANGUAGE: English

L2 ANSWER 70 OF 375 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 23

AN 1998:219828 CAPLUS
DN 128:279007
TI ***Colostrinin*** , isolation thereof, and use in treatment of disorders of the central nervous system and immune system
IN Janusz, Marin; Lisowski, Jozef; Dubowska-Inglot, Anna
PA Ludwick Hirszfeld Institute of Immunology and Experimental Therapy Polish Academy of Sciences, Pol.; Georgiades Biotech Ltd.; Janusz, Marin; Lisowski, Jozef; Dubowska-Inglot, Anna
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9814473	A1	19980409	WO 1997-GB2721	19971003
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PL 185442	B1	20030530	PL 1996-316416	19961003
CN 1238782	A	19991215	CN 1997-198535	19970310
AU 9745651	A1	19980424	AU 1997-45651	19971003
ZA 9708885	A	19990726	ZA 1997-8885	19971003
GB 2333453	A1	19990728	GB 1999-8331	19971003
GB 2333453	B2	20010530		
EP 932623	A1	19990804	EP 1997-944005	19971003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9712259	A	20000125	BR 1997-12259	19971003
GB 2352176	A1	20010124	GB 2000-23325	19971003
GB 2352176	B2	20010530		
JP 2001501929	T2	20010213	JP 1998-516329	19971003
NZ 510681	A	20021220	NZ 1997-510681	19971003
MX 9903108	A	20000531	MX 1999-3108	19990331
KR 2000048886	A	20000725	KR 1999-702904	19990402
AU 761148	B2	20030529	AU 2001-95147	20011128
AU 2001095147	A5	20020117		
PRAI PL 1996-316416	A	19961003		
AU 1997-45651	A3	19971003		
GB 1999-8331	A3	19971003		
NZ 1997-334911	A1	19971003		
WO 1997-GB2721	W	19971003		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 71 OF 375 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 24
AN 1998:392640 BIOSIS
DN PREV199800392640
TI Effect of ***colostrinin*** , an immunomodulatory proline-rich polypeptide from ovine colostrum, on sialidase and beta-galactosidase activities in murine thymocytes.
AU Sokal, Izabela; Janusz, Maria; Miecznikowska, Hanna; Kupryszewski, Gotfryd; Lisowski, Jozef [Reprint author]
CS Dep. Immunochem., Inst. Immunol. and Exp. Ther., Pol. Acad. Sci., Weigla 12, 53-114 Wroclaw, Poland
SO Archivum Immunologiae et Therapiae Experimentalis, (1998) Vol. 46, No. 3, pp. 193-198. print.
CODEN: AITEAT. ISSN: 0004-069X.
DT Article
LA English
ED Entered STN: 10 Sep 1998
Last Updated on STN: 10 Sep 1998

L2 ANSWER 72 OF 375 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
AN 1998:891393 SCISEARCH
GA The Genuine Article (R) Number: 136CD
TI Facilitation of learning and some other behavioral effects of ***colostrinin***
AU Popik P (Reprint); Bobula B; Galoch Z; Wida M; Kozela E; Janusz M; Lisowski J

CS POLISH ACAD SCI, INST PHARMACOL, PL-31343 KRAKOW, POLAND; POLISH ACAD SCI, INST IMMUNOL & EXPT THERAPY, PL-53114 WROCLAW, POLAND
CYA POLAND
SO EUROPEAN CYTOKINE NETWORK, (SEP 1998) Vol. 9, No. 3, pp. 167-167. Publisher: JOHN LIBBEY EUROTEXT LTD, 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE. ISSN: 1148-5493.
DT Conference; Journal
FS LIFE
LA English
REC Reference Count: 0

L2 ANSWER 73 OF 375 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN DUPLICATE 25
AN 1998:303823 BIOSIS
DN PREV199800303823
TI Tumor-associated antigens are cytokine inducers and hyporeactivity factors to the immune system.
AU Inglot, Anna D.; Gelder, Frank; Georgiades, Jerry A. [Reprint author]
CS Georgiades Found. Treatment Chronic Viral Dis., Stafford, TX 77477, USA
SO Biotherapy (Dordrecht), (1998) Vol. 11, No. 1, pp. 27-37. print. ISSN: 0921-299X.
DT Article
LA English
ED Entered STN: 15 Jul 1998
Last Updated on STN: 15 Jul 1998

L2 ANSWER 74 OF 375 CEABA-VTB COPYRIGHT 2003 DECHEMA on STN
AN 1998(07):5055 CEABA-VTB FS B
DN CEABA: 1998:9712891
TI ReGen to raise pounds 2.5 million
CS ReGen Therapeutics, UK
SO Pharm. Bus. News (1998) 14(321), p.19
CODEN: PBNEEH ISSN: 0956-0661
DT Journal
LA English

L2 ANSWER 75 OF 375 CIN COPYRIGHT 2003 ACS on STN
AN 27(32):36577Q CIN
TI ReGen to raise .pnd.2.5 million
SO Pharm. Bus. News, 15 Jul 1998 (19980715), 14(321), p. 19. ISSN: 0956-0661; CODEN: PBNEEH.
LA English

L2 ANSWER 76 OF 375 DRUGU COPYRIGHT 2003 THOMSON DERWENT on STN
AN 1997-04276 DRUGU T
TI ***Colostrinin*** - new cytokine with psycho-immuno-enhancing activity, for treatment of Alzheimer's disease.
AU Leszek J; Inglot A D; Janusz M; Lisowski J
CS Univ.Wroclaw
LO Wroclaw, Pol.
SO J.Neural Transm. (103, No. 10, XXXIX, 1996)
CODEN: JNTMAH ISSN: 0300-9564
AV Department of Psychiatry, University of Wroclaw, Wroclaw, Poland.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L2 ANSWER 77 OF 375 ADISINSIGHT COPYRIGHT (C) 2003 Adis Data Information BV on STN
ACCESSION NUMBER: 2000:995 ADISINSIGHT
SOURCE: Adis R&D Insight
DOCUMENT NO: 014121
CHANGE DATE: Oct 20, 2003
GENERIC NAME: ***Colostrinin***
MOLECULAR FORMULA:Unspecified
STRUCTURE:
STRUCTURE DIAGRAM IS NOT AVAILABLE

EPHMRA ATC CODE: N7D9 All other anti-Alzheimer products
WHO ATC CODE: N06D-X Other anti-dementia drugs
HIGHEST DEV. PHASE: Phase II

COMPANY INFORMATION
ORIGINATOR: Nonindustrial source (Poland); Nonindustrial source

(Unknown)
PARENT: Nonindustrial source
LICENSEE: ReGen Therapeutics

OTHER SOURCES: 800741417; 809026793
WORD COUNT: 503

L2 ANSWER 78 OF 375 ADISNEWS COPYRIGHT (C) 2003 Adis Data Information BV on STN
ACCESSION NUMBER: 2002:3414 ED: 16 Jul 2002 UP: 16 Jul 2002
DOCUMENT NUMBER: 11738324-809007291
TITLE: Product news: ***Colostrinin*** beneficial in Alzheimer's disease.
SOURCE: INPHARMA 16 Jul 2002 ISSN: 1173-8324
DOCUMENT TYPE: (MIX)
WORD COUNT: 122

L2 ANSWER 79 OF 375 BIOCOMMERCE COPYRIGHT 2003 BioCommerce Data Ltd. on STN
AN 1046113 BIOCOMMERCE FS Directory
CO ReGen Therapeutics Plc (46652)
CA 4th Floor, Suite 406, Langham House
29-30 Margaret Street
W1W 8SA London
UK

TL Telephone: (020) 79070910
Telefax: (020) 79070911
E-mail: head.office@regentherapeutics.com
URL: http://www.regentherapeutics.com

L2 ANSWER 80 OF 375 BIOCOMMERCE COPYRIGHT 2003 BioCommerce Data Ltd. on STN
AN 0175441 BIOCOMMERCE FS Abstract
CO ReGen Therapeutics Plc (46652), UK
Polish Academy of Sciences, Institute of Immunology and Experimental Therapy (18724), Poland
Dr Rentschler Biotechnologie GmbH (DORETEC) (42053), Germany
Georgiades Foundation (47320), UK
Georgiades Biotech (47321), UK
PolyMASC Pharmaceuticals plc (37200), UK
Rentschler Biotechnology GmbH & Co KG (48587), Germany
SO Scrip Daily News Alert, 20 OCT 1998, vol. 2380, Page(s) 1.
Scrip, 21 OCT 1998, Page(s) 11.
Financial Times, 16 OCT 1998, Page(s) 23.
TC (Company information)

L2 ANSWER 81 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32223 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #17.

L2 ANSWER 82 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32222 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #16.

L2 ANSWER 83 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32221 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #15.

L2 ANSWER 84 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32220 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #14.

L2 ANSWER 85 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32219 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #13.

L2 ANSWER 86 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32218 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #12.

L2 ANSWER 87 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32217 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206

DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #11.

L2 ANSWER 88 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32216 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #10.

L2 ANSWER 89 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32215 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #9.

L2 ANSWER 90 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32214 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #8.

L2 ANSWER 91 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32213 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #7.

L2 ANSWER 92 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32212 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A

PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #6.

L2 ANSWER 93 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32211 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #5.

L2 ANSWER 94 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32210 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #4.

L2 ANSWER 95 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32209 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #3.

L2 ANSWER 96 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32208 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #2.

L2 ANSWER 97 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN ABG32207 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful

for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #1.

L2 ANSWER 98 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20261 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #32.

L2 ANSWER 99 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20259 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #31.

L2 ANSWER 100 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20258 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #30.

L2 ANSWER 101 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20257 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #29.

L2 ANSWER 102 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20256 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a

patient comprises a blood cell regulator selected from
colostrinin , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #28.

L2 ANSWER 103 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20255 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from
colostrinin , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #27.

L2 ANSWER 104 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20254 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from
colostrinin , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #26.

L2 ANSWER 105 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20253 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from
colostrinin , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #25.

L2 ANSWER 106 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20252 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from
colostrinin , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #24.

L2 ANSWER 107 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20251 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from

colostrinin , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #23.

L2 ANSWER 108 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20250 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from
colostrinin , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #22.

L2 ANSWER 109 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20249 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from
colostrinin , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #21.

L2 ANSWER 110 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20248 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from
colostrinin , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #20.

L2 ANSWER 111 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20247 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from
colostrinin , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #19.

L2 ANSWER 112 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20246 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from
colostrinin , its constituent peptide and/or analog -

IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #18.

L2 ANSWER 113 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20245 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #17.

L2 ANSWER 114 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20244 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #16.

L2 ANSWER 115 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20243 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #15.

L2 ANSWER 116 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20242 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #14.

L2 ANSWER 117 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20241 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I

PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #13.

L2 ANSWER 118 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20240 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #12.

L2 ANSWER 119 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20239 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #11.

L2 ANSWER 120 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20237 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #10.

L2 ANSWER 121 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20236 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #9.

L2 ANSWER 122 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20235 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.

PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #8.

L2 ANSWER 123 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20234 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #7.

L2 ANSWER 124 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20233 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #6.

L2 ANSWER 125 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20232 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #5.

L2 ANSWER 126 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20231 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #4.

L2 ANSWER 127 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20230 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p

AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #3.

L2 ANSWER 128 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20229 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #2.

L2 ANSWER 129 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE20228 peptide DGENE
TI Composition useful for the modulation of blood cell proliferation in a patient comprises a blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013850 A1 20020221 51p
AI WO 2000-US22776 20000817
PRAI WO 2000-US22776 20000817
DT Patent
LA English
OS 2002-269151 [31]
DESC ***Colostrinin*** constituent peptide #1.

L2 ANSWER 130 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAO14610 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 32.

L2 ANSWER 131 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAO14608 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 31.

L2 ANSWER 132 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAO14607 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817

PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 30.

L2 ANSWER 133 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014606 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 29.

L2 ANSWER 134 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014605 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 28.

L2 ANSWER 135 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014604 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 27.

L2 ANSWER 136 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014603 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 26.

L2 ANSWER 137 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014602 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817

DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 25.

L2 ANSWER 138 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014601 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 24.

L2 ANSWER 139 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014600 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 23.

L2 ANSWER 140 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014599 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 22.

L2 ANSWER 141 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014598 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 21.

L2 ANSWER 142 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014597 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent

LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 20.

L2 ANSWER 143 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAO14596 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 19.

L2 ANSWER 144 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAO14595 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 18.

L2 ANSWER 145 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAO14594 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 17.

L2 ANSWER 146 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAO14593 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 16.

L2 ANSWER 147 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAO14592 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English

OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 15.

L2 ANSWER 148 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014591 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 14.

L2 ANSWER 149 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014590 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 13.

L2 ANSWER 150 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014589 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 12.

L2 ANSWER 151 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014588 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 11.

L2 ANSWER 152 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014586 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]

DESC Neural cell regulatory ***colostrinin*** peptide 10.

L2 ANSWER 153 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014585 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 9.

L2 ANSWER 154 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014584 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 8.

L2 ANSWER 155 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014583 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 7.

L2 ANSWER 156 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014582 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 6.

L2 ANSWER 157 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014581 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 5.

L2 ANSWER 158 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014580 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 4.

L2 ANSWER 159 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014579 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 3.

L2 ANSWER 160 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014578 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 2.

L2 ANSWER 161 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AA014577 peptide DGENE
TI Promoting cell differentiation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analog -
IN Boldogh I; Stanton J G; Hughes T K
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2002013851 A1 20020221 37p
AI WO 2000-US22777 20000817
PRAI WO 2000-US22777 20000817
DT Patent
LA English
OS 2002-269152 [31]
DESC Neural cell regulatory ***colostrinin*** peptide 1.

L2 ANSWER 162 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51067 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 163 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51066 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 159-173).

L2 ANSWER 164 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51065 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 203-214).

L2 ANSWER 165 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51064 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (annexin amino acids 203-220).

L2 ANSWER 166 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51063 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 214-222).

L2 ANSWER 167 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51062 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817

DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 202-208).

L2 ANSWER 168 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51061 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 180-201).

L2 ANSWER 169 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51060 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 174-179).

L2 ANSWER 170 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51059 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 164-173).

L2 ANSWER 171 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51058 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 157-163).

L2 ANSWER 172 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51057 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.

(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 139-156).

L2 ANSWER 173 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51056 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 121-138).

L2 ANSWER 174 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51055 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 103-120).

L2 ANSWER 175 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51054 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 93-102).

L2 ANSWER 176 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51053 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 84-92).

L2 ANSWER 177 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51052 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood

cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 74-83).

L2 ANSWER 178 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51051 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 179 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51050 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 180 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51049 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 181 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51048 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 182 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51047 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 183 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51046 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 184 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51045 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 185 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51044 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 186 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51043 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817

DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 187 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51042 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 188 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51041 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 189 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51040 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 190 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51039 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 191 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51038 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.

(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 192 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51037 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 193 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAM51036 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L2 ANSWER 194 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07204 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC Modified ***colostrinin*** cyclic peptide #10.

L2 ANSWER 195 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07203 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC Modified ***colostrinin*** cyclic peptide #9.

L2 ANSWER 196 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07202 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the

immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -

IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC Modified ***colostrinin*** cyclic peptide #8.

L2 ANSWER 197 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07201 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -

IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC Modified ***colostrinin*** cyclic peptide #7.

L2 ANSWER 198 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07200 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -

IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC Modified ***colostrinin*** cyclic peptide #6.

L2 ANSWER 199 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07199 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -

IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC Modified ***colostrinin*** cyclic peptide #5.

L2 ANSWER 200 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07198 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -

IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC Modified ***colostrinin*** cyclic peptide #4.

L2 ANSWER 201 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07197 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin***
-
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC Modified ***colostrinin*** cyclic peptide #3.

L2 ANSWER 202 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07196 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin***
-
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC Modified ***colostrinin*** cyclic peptide #2.

L2 ANSWER 203 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07195 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin***
-
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC Modified ***colostrinin*** cyclic peptide #1.

L2 ANSWER 204 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07194 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin***
-
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC ***Colostrinin*** peptide 10.

L2 ANSWER 205 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07193 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin***
-
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126

DT Patent
LA English
OS 2001-488775 [53]
DESC ***Colostrinin*** peptide 9.

L2 ANSWER 206 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07192 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC ***Colostrinin*** peptide 8.

L2 ANSWER 207 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07191 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC ***Colostrinin*** peptide 7.

L2 ANSWER 208 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07190 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC ***Colostrinin*** peptide 6.

L2 ANSWER 209 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07189 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC ***Colostrinin*** peptide 5.

L2 ANSWER 210 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07188 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -
IN Georgiades J A

PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC ***Colostrinin*** peptide 4.

L2 ANSWER 211 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07187 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC ***Colostrinin*** peptide 3.

L2 ANSWER 212 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07186 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC ***Colostrinin*** peptide 2.

L2 ANSWER 213 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAE07185 peptide DGENE
TI Peptide useful as an inter alia in the treatment of e.g. disorders of the immune system and the central nervous system comprises ten amino-terminal amino acid sequence derived from peptides present in ***colostrinin*** -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001055199 A1 20010802 40p
AI WO 2001-GB329 20010126
PRAI GB 2000-1825 20000126
DT Patent
LA English
OS 2001-488775 [53]
DESC ***Colostrinin*** peptide 1.

L2 ANSWER 214 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72279 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 34.

L2 ANSWER 215 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72278 peptide DGENE

TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 33.

L2 ANSWER 216 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72277 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 32.

L2 ANSWER 217 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72276 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 31.

L2 ANSWER 218 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72275 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 30.

L2 ANSWER 219 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72274 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p

AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 29.

L2 ANSWER 220 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72273 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 28.

L2 ANSWER 221 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72272 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 27.

L2 ANSWER 222 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72271 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 26.

L2 ANSWER 223 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72270 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 25.

L2 ANSWER 224 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN

AN AAB72269 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 24.

L2 ANSWER 225 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72268 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 23.

L2 ANSWER 226 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72267 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 22.

L2 ANSWER 227 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72266 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 21.

L2 ANSWER 228 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72265 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.

PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 20.

L2 ANSWER 229 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72264 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 19.

L2 ANSWER 230 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72263 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 18.

L2 ANSWER 231 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72262 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 17.

L2 ANSWER 232 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72261 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 16.

L2 ANSWER 233 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72260 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 15.

L2 ANSWER 234 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72259 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 14.

L2 ANSWER 235 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72258 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 13.

L2 ANSWER 236 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72257 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 12.

L2 ANSWER 237 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72256 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.

(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 11.

L2 ANSWER 238 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72255 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 10.

L2 ANSWER 239 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72254 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 9.

L2 ANSWER 240 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72253 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 8.

L2 ANSWER 241 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72252 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 7.

L2 ANSWER 242 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72251 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 6.

L2 ANSWER 243 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72250 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 5.

L2 ANSWER 244 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72249 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 4.

L2 ANSWER 245 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72248 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 3.

L2 ANSWER 246 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72247 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J

PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 2.

L2 ANSWER 247 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72246 peptide DGENE
TI Inducing a cytokine and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived cytokine inducing peptide SEQ ID 1.

L2 ANSWER 248 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72563 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #32.

L2 ANSWER 249 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72562 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #31.

L2 ANSWER 250 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72561 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #30.

L2 ANSWER 251 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72560 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and

treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #29.

L2 ANSWER 252 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72559 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #28.

L2 ANSWER 253 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72558 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #27.

L2 ANSWER 254 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72557 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #26.

L2 ANSWER 255 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72556 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #25.

L2 ANSWER 256 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72555 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -

IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #24.

L2 ANSWER 257 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72554 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #23.

L2 ANSWER 258 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72553 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #22.

L2 ANSWER 259 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72552 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #21.

L2 ANSWER 260 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72551 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #20.

L2 ANSWER 261 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72550 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I

PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #19.

L2 ANSWER 262 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72549 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #18.

L2 ANSWER 263 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72548 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #17.

L2 ANSWER 264 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72547 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #16.

L2 ANSWER 265 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72546 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #15.

L2 ANSWER 266 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72545 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.

PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #14.

L2 ANSWER 267 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72544 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #13.

L2 ANSWER 268 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72543 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #12.

L2 ANSWER 269 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72542 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #11.

L2 ANSWER 270 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72541 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #10.

L2 ANSWER 271 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72540 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p

AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #9.

L2 ANSWER 272 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72539 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #8.

L2 ANSWER 273 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72538 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #7.

L2 ANSWER 274 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72537 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #6.

L2 ANSWER 275 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72536 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #5.

L2 ANSWER 276 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72535 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817

PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #4.

L2 ANSWER 277 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72534 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #3.

L2 ANSWER 278 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72533 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #2.

L2 ANSWER 279 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72532 Peptide DGENE
TI Use of ***colostrinin*** , its constituent peptide or analog as a neural cell regulator, for promoting neural cell differentiation and treating damaged neural cells in a patient -
IN Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012651 A2 20010222 35p
AI WO 2000-US22774 20000817
PRAI US 1999-149633 19990817
DT Patent
LA English
OS 2001-226545 [23]
DESC ***Colostrinin*** peptide #1.

L2 ANSWER 280 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72531 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #32.

L2 ANSWER 281 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72530 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817

DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #31.

L2 ANSWER 282 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72529 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #30.

L2 ANSWER 283 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72528 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #29.

L2 ANSWER 284 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72527 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #28.

L2 ANSWER 285 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72526 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #27.

L2 ANSWER 286 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72525 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent

LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #26.

L2 ANSWER 287 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72524 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #25.

L2 ANSWER 288 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72523 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #24.

L2 ANSWER 289 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72522 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #23.

L2 ANSWER 290 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72521 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #22.

L2 ANSWER 291 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72520 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English

OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #21.

L2 ANSWER 292 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72519 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #20.

L2 ANSWER 293 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72518 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #19.

L2 ANSWER 294 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72517 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #18.

L2 ANSWER 295 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72516 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #17.

L2 ANSWER 296 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72515 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]

DESC ***Colostrinin*** peptide #16.

L2 ANSWER 297 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72514 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #15.

L2 ANSWER 298 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72513 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #14.

L2 ANSWER 299 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72512 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #13.

L2 ANSWER 300 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72511 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #12.

L2 ANSWER 301 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72510 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #11.

L2 ANSWER 302 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72509 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #10.

L2 ANSWER 303 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72508 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #9.

L2 ANSWER 304 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72507 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #8.

L2 ANSWER 305 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72506 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #7.

L2 ANSWER 306 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72505 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #6.

L2 ANSWER 307 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72504 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #5.

L2 ANSWER 308 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72503 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #4.

L2 ANSWER 309 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72502 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #3.

L2 ANSWER 310 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72501 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #2.

L2 ANSWER 311 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB72500 Peptide DGENE
TI Modulating oxidative stress level in a cell, involves contacting the cell with an oxidative stress regulator selected from ***colostrinin*** , its constituent peptide, analog or their combinations -
IN Stanton G J; Hughes T K; Boldogh I
PA (TEXA) UNIV TEXAS SYSTEM.
PI WO 2001012650 A2 20010222 48p
AI WO 2000-US22665 20000817
PRAI US 1999-149310 19990817
DT Patent
LA English
OS 2001-218342 [22]
DESC ***Colostrinin*** peptide #1.

L2 ANSWER 312 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN

AN AAB59357 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #17.

L2 ANSWER 313 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59356 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #16.

L2 ANSWER 314 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59355 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #15.

L2 ANSWER 315 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59354 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #14.

L2 ANSWER 316 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59353 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English

OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #13.

L2 ANSWER 317 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59352 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #12.

L2 ANSWER 318 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59351 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #11.

L2 ANSWER 319 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59350 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #10.

L2 ANSWER 320 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59349 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #9.

L2 ANSWER 321 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59348 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p

AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #8.

L2 ANSWER 322 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59347 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #7.

L2 ANSWER 323 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59346 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #6.

L2 ANSWER 324 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59345 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #5.

L2 ANSWER 325 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59344 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #4.

L2 ANSWER 326 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59343 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases

characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #3.

L2 ANSWER 327 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59342 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #2.

L2 ANSWER 328 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59341 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment derived sequence #1.

L2 ANSWER 329 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59340 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment D-1.

L2 ANSWER 330 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59339 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment C-14.

L2 ANSWER 331 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN

AN AAB59338 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment C-13.

L2 ANSWER 332 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59337 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment C-12.

L2 ANSWER 333 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59336 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment C-11.

L2 ANSWER 334 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59335 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment C-10.

L2 ANSWER 335 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59334 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English

OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment C-9.

L2 ANSWER 336 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59333 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment C-8.

L2 ANSWER 337 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59332 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment C-7.

L2 ANSWER 338 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59331 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment C-6.

L2 ANSWER 339 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59330 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment C-5.

L2 ANSWER 340 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59329 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p

AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment C-4.

L2 ANSWER 341 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59328 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment C-3.

L2 ANSWER 342 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59327 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment C-2.

L2 ANSWER 343 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59326 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment C-1.

L2 ANSWER 344 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59325 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment B-10.

L2 ANSWER 345 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59324 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases

characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment B-9.

L2 ANSWER 346 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59323 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment B-8.

L2 ANSWER 347 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59322 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment B-7.

L2 ANSWER 348 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59321 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment B-6.

L2 ANSWER 349 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59320 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment B-5.

L2 ANSWER 350 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN

AN AAB59319 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment B-4.

L2 ANSWER 351 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59318 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment B-3.

L2 ANSWER 352 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59317 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment B-2.

L2 ANSWER 353 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59316 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment B-1.

L2 ANSWER 354 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59315 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English

OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment A-7.

L2 ANSWER 355 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59314 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment A-5.

L2 ANSWER 356 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59313 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment A-4.

L2 ANSWER 357 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59312 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment A-3.

L2 ANSWER 358 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59311 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p
AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment A-2.

L2 ANSWER 359 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAB59310 Peptide DGENE
TI Peptides having an N-terminal amino acid sequence isolated from ***colostrinin*** for treating e.g. disorders of the central nervous system and immune system, viral and bacterial infections, and diseases characterized by amyloid plaques -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2000075173 A2 20001214 63p

AI WO 2000-GB2128 20000602
PRAI GB 1999-12852 19990602
DT Patent
LA English
OS 2001-071058 [08]
DESC Ewe ***colostrinin*** peptide fragment A-1.

L2 ANSWER 360 OF 375 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN AAW42101 peptide DGENE
TI Use of ***colostrinin*** , or derived nonapeptide for treating chronic diseases of the central nervous system - and immune system, also as dietary supplement and for inhibiting development of Alzheimer's disease
IN Dubowska-Inglot A; Janusz M; Lisowski J
PA (GEOR-N) GEORGIADES BIOTECH LTD.
(HIRS-N) HIRSZFELD INST IMMUNOLOGY & EXPERIMENTAL.
PI WO 9814473 A1 19980409 34p
AI WO 1997-GB2721 19971003
PRAI PL 1996-316416 19961003
DT Patent
LA English
OS 1998-250967 [22]
DESC ***Colostrinin*** derived nanopeptide.

L2 ANSWER 361 OF 375 DRUGU COPYRIGHT 2003 THOMSON DERWENT on STN
AN 48215 DRUGU
FS Registry
DDRN DR9700630
DDN ***COLOSTRININ***
SS PROTEIN

L2 ANSWER 362 OF 375 IMSRESEARCH COPYRIGHT 2003 IMSWORLD on STN

ACCESSION NUMBER: 2000:177 IMSRESEARCH
SOURCE: R&D Focus, (15 Jul 2002)
TRADE NAME: ***COLOSTRININ***
CHEMICAL NAME: unspecified
CAS REGISTRY NO.: 252266-11-8
STRUCTURE:

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
DERIVATIVE(S): 252266-11-8 ***colostrinin***
CLASSIFICATION: N7D9 All Other Anti-Alzheimer Products
HIGHEST DEV. PHASE: Phase II (40)

COMPANY INFORMATION:

Type	Company	Nationality
Originator	ReGen Therapeutics	United Kingdom

L2 ANSWER 363 OF 375 PHAR COPYRIGHT 2003 PJB on STN
AN 17177 PHAR
DN 028382
CN ***Colostrinin***
CN RG-010
CN ***Colostrinin*** (CAS)
RN 252266-11-8
STA Active

CO

Type	Company Name (Country)	Development Status
Originator	ReGen Therapeutics (United Kingdom)	Phase II Clinical Trial
Licensee	Rentschler (Germany)	Phase II Clinical Trial

PI WO 9965329
PRAI GB 19980616
SO Pharmaprojects. PJB Publications Ltd., Richmond, Surrey, UK
TX ***Colostrinin*** is a cytokine inducer isolated from sheep's milk, under development by ReGen Therapeutics for the treatment of Alzheimer's disease (AD). It has been isolated from colostrum, which has immunomodulatory properties. It may also be effective in the treatment of dementia and hepatitis-B and cancer (Biotherapy, 1998, 11, 27; Scrip, 1998, 2380, 11; Regen, AGM, Jun

2003).MarketingRentschler is supervising clinical trials in Poland and will conduct Phase II trials in Germany. It will also be responsible for submitting registration applications in Poland and Europe.ClinicalPhase IIA European dose-ranging Phase IIb/III trial, including patients with early-stage Alzheimer's disease, was expected in the 3rd qtr of 2002 (not started as of Jul 2003) (Scrip Daily Online, 8 Jul 2002, S00762244; Direct communication, ReGen, 25 Nov 2002; Wall Street Transapt, Regen, May 2003). In a completed 6-centre placebo-controlled Phase II clinical trial in Poland in 106 patients with mild-to-moderate AD, ***Colostrinin*** was reported to have failed to show a significant treatment effect; however, further analysis of interim data at 15wk showed that it did meet its primary endpoint of significant treatment effect as measured by ADAS-cog, with 40% of patients showing benefit, and showed statistical significance in IADL. At 30wk, 33% of patients continued to benefit, and there were no drug-related serious adverse events or safety concerns. Best results were seen in patients with mild symptoms (Scrip Daily Online, 25 Mar 2002, S00749096 and 8 Jul 2002, S00762244). In a double-blind, placebo-controlled trial of ovine ***Colostrinin*** in 47 AD patients in Poland, 11/16 patients treated with ***Colostrinin*** improved and 5 stabilized after 1yr cf selenium and placebo groups, in which there were no improvements, and 3/16 and 11/15 patients stabilized, respectively. In a 12mth follow up of ***Colostrinin*** - and selenium-treated patients, 13/16 and 1/16 stabilized, respectively. After 2yr, average MMSE scores were 2.7 points higher and 5.2 points lower, respectively. Side-effects included anxiety, stimulation, insomnia and tiredness (Company prospectus, ReGen, Oct 1998).PreclinicalScreening for anticancer activity is planned (Regen, AGM, Jun 2003). 3 UK patents have been granted (Wall Street Transcript, Regen, May 2003).LicensingReGen Therapeutics is looking for a partner to conduct Phase IIb trials (Scrip Daily Online, 8 Jul 2002, S00762244). Updated by AZ on 16/7/2003.

DSTA World: Phase II Clinical Trial
Argentina: Available for Licensing
Australia: Available for Licensing
Austria: Available for Licensing
Belgium: Available for Licensing
Brazil: Available for Licensing
Canada: Available for Licensing
Chile: Available for Licensing
China: Available for Licensing
Colombia: Available for Licensing
Denmark: Available for Licensing
Finland: Available for Licensing
France: Available for Licensing
Germany: Available for Licensing
Greece: Available for Licensing
Hong Kong: Available for Licensing
India: Available for Licensing
Ireland: Available for Licensing
Israel: Available for Licensing
Italy: Available for Licensing
Japan: Available for Licensing
Luxembourg: Available for Licensing
Malaysia: Available for Licensing
Mexico: Available for Licensing
Netherlands: Available for Licensing
Norway: Available for Licensing
New Zealand: Available for Licensing
Peru: Available for Licensing
Philippines: Available for Licensing
Portugal: Available for Licensing
Russian Federation: Available for Licensing
South Africa: Available for Licensing
Korea, Republic of: Available for Licensing
Spain: Available for Licensing
Sweden: Available for Licensing
Switzerland: Available for Licensing
Thailand: Available for Licensing
Turkey: Available for Licensing
United Kingdom: Preclinical; Available for Licensing
United States: Available for Licensing
Venezuela: Available for Licensing

CC N6D Cognition enhancer
J5Z Antiviral, other

K6Z Anticancer, other
CT Indication: Alzheimer's disease
ORGM NP-A (Natural product, animal)
RTE A-PO (Alimentary, po)
RDAT 20030716 RNTE ##Act##New Therapeutic Activity Anticancer, other (K6Z)
20020325 ##Est##Status changed Phase II Clinical Trial
20011213 ##Est##Licensing Opportunity Worldwide
19981030 ##Est##New Product
NRAT 6:Novelty Rating - Leading Compound
MRAT 2:Market Rating - US$ 501-2000 million
SRAT 4:Speed Rating - Faster than Average
TRAT 12:Total Rating - Total Rating
PHCD IM-AG; Immunostimulant; Physiological, Hormonal, Immunostimulant; Immunogenic agent; P-H-IM-AG.
PHCD P; P-AG; P-H; P-H-AG; P-H-IM; P-H-IM-AG; H; H-AG; H-IM; H-IM-AG; IM; IM-AG.

LN

Therapy (CC)	Pharmacology (PHCD)	Status (DSTC)
N6D	IM-AG	C2
J5Z	IM-AG	P
K6Z	UN	P

LCDAT 20030716: AZ : Anticancer potential reported

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L2 ANSWER 364 OF 375 PHARMAML COPYRIGHT 2003 MARKETLETTER on STN
AN 1664249 PHARMAML
TI ReGen lifted on 30-week ***Colostrinin*** data
SO Marketletter July 15, 2002
DT Newsletter
WC 240

L2 ANSWER 365 OF 375 PHARMAML COPYRIGHT 2003 MARKETLETTER on STN
AN 1663118 PHARMAML
TI ReGen Alzheimer's drug effective in AD
SO Marketletter May 13, 2002
DT Newsletter
WC 89

L2 ANSWER 366 OF 375 PHARMAML COPYRIGHT 2003 MARKETLETTER on STN
AN 1662347 PHARMAML
TI ReGen shares dive as AD drug disappoints
SO Marketletter April 1, 2002
DT Newsletter
WC 199

L2 ANSWER 367 OF 375 PHARMAML COPYRIGHT 2003 MARKETLETTER on STN
AN 1656433 PHARMAML
TI ReGen's ***Colostrinin*** trials continue
SO Marketletter April 17, 2001
DT Newsletter
WC 204

L2 ANSWER 368 OF 375 PHARMAML COPYRIGHT 2003 MARKETLETTER on STN
AN 1642616 PHARMAML
TI ReGen Looking To Raise L2.5 Million
SO Marketletter July 2, 1998
DT Newsletter
WC 164

L2 ANSWER 369 OF 375 FROSTI COPYRIGHT 2003 LFRA on STN
AN 516123 FROSTI
TI Dietary supplement.
IN Georgiades J.A.
PA Regen Biotech Ltd
SO PCT Patent Application
PI WO 9965329 A2
AI 19990615
PRAI United Kingdom 19980616

DT Patent
LA English
SL English

L2 ANSWER 370 OF 375 FROSTI COPYRIGHT 2003 LFRA on STN
AN 596125 FROSTI
TI Peptide fragments of ***colostrinin*** and their use.
IN Georgiades J.A.
PA Regen Therapeutics Plc
SO UK Patent Application
PI GB 2374871 A
 WO 2001055199 20010802
AI 20010126
PRAI United Kingdom 20000126
DT Patent
LA English
SL English

L2 ANSWER 371 OF 375 FROSTI COPYRIGHT 2003 LFRA on STN
AN 552220 FROSTI
TI Dietary supplement.
IN Georgiades J.A.
PA ReGen Biotech Ltd
SO UK Patent Application
PI GB 2354153 A
 WO 9965329 19991223
AI 19990615
PRAI United Kingdom 19980616
DT Patent
LA English
SL English

L2 ANSWER 372 OF 375 FROSTI COPYRIGHT 2003 LFRA on STN
AN 621795 FROSTI
TI Peptides derived from ***colostrinin*** .
IN Georgiades J.A.
PA Regen Therapeutics plc
SO European Patent Application
PI EP 1341816 A2
 WO 2002046211 20020613
AI 20011205
PRAI United Kingdom 20001206
DT Patent
LA English
SL English

L2 ANSWER 373 OF 375 FROSTI COPYRIGHT 2003 LFRA on STN
AN 595448 FROSTI
TI Peptide fragments of ***colostrinin*** .
IN Georgiades J.A.
PA Regen Therapeutics plc
SO European Patent Application
PI EP 1240193 A2
 WO 2000075173 20001214
AI 20000602
PRAI United Kingdom 19990602
DT Patent
LA German
SL German

L2 ANSWER 374 OF 375 FROSTI COPYRIGHT 2003 LFRA on STN
AN 587031 FROSTI
TI Peptides derived from ***colostrinin*** .
IN Georgiades J.A.
PA Regen Therapeutics plc
SO PCT Patent Application
PI WO 2002046211 A2
AI 20011205
PRAI United Kingdom 20001206
DT Patent
LA English
SL English

L2 ANSWER 375 OF 375 FROSTI COPYRIGHT 2003 LFRA on STN
AN 564005 FROSTI
TI Peptide fragments of ***colostrinin*** and their use.

IN Georgiades J.A.
PA Regen Therapeutics Plc
SO PCT Patent Application
PI WO 2001055199 A1
AI 20010126
PRAI United Kingdom 20000126
DT Patent
LA English
STN INTERNATIONAL LOGOFF AT 15:51:23 ON 08 DEC 2003